1
|
Nojiri M, Takata T, Hu N, Sakurai Y, Suzuki M, Tanaka H. Neutron flux evaluation algorithm with a combination of Monte Carlo and removal-diffusion calculation methods for boron neutron capture therapy. Med Phys 2024; 51:3711-3724. [PMID: 38205862 DOI: 10.1002/mp.16931] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2023] [Revised: 12/05/2023] [Accepted: 12/20/2023] [Indexed: 01/12/2024] Open
Abstract
BACKGROUND In Japan, the clinical treatment of boron neutron capture therapy (BNCT) has been applied to unresectable, locally advanced, and recurrent head and neck carcinomas using an accelerator-based neutron source since June of 2020. Considering the increase in the number of patients receiving BNCT, efficiency of the treatment planning procedure is becoming increasingly important. Therefore, novel and rapid dose calculation algorithms must be developed. We developed a novel algorithm for calculating neutron flux, which comprises of a combination of a Monte Carlo (MC) method and a method based on the removal-diffusion (RD) theory (RD calculation method) for the purpose of dose calculation of BNCT. PURPOSE We present the details of our novel algorithm and the verification results of the calculation accuracy based on the MC calculation result. METHODS In this study, the "MC-RD" calculation method was developed, wherein the RD calculation method was used to calculate the thermalization process of neutrons and the MC method was used to calculate the moderation process. The RD parameters were determined by MC calculations in advance. The MC-RD calculation accuracy was verified by comparing the results of the MC-RD and MC calculations with respect to the neutron flux distributions in each of the cubic and head phantoms filled with water. RESULTS Comparing the MC-RD calculation results with those of MC calculations, it was found that the MC-RD calculation accurately reproduced the thermal neutron flux distribution inside the phantom, with the exception of the region near the surface of the phantom. CONCLUSIONS The MC-RD calculation method is useful for the evaluation of the neutron flux distribution for the purpose of BNCT dose calculation, except for the region near the surface.
Collapse
Affiliation(s)
- Mai Nojiri
- Department of Nuclear Engineering, Graduate School of Engineering, Kyoto University, Kyoto, Japan
| | - Takushi Takata
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Osaka, Japan
| | - Naonori Hu
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Osaka, Japan
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan
| | - Yoshinori Sakurai
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Osaka, Japan
| | - Minoru Suzuki
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Osaka, Japan
| | - Hiroki Tanaka
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Osaka, Japan
| |
Collapse
|
2
|
Hu N, Nakao M, Ozawa S, Takata T, Tanaka H, Nihei K, Ono K, Suzuki M. Application of stoichiometric CT number calibration method for dose calculation of tissue heterogeneous volumes in boron neutron capture therapy. Med Phys 2024. [PMID: 38669482 DOI: 10.1002/mp.17093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2023] [Revised: 04/09/2024] [Accepted: 04/10/2024] [Indexed: 04/28/2024] Open
Abstract
BACKGROUND Monte Carlo simulation code is commonly used for the dose calculation of boron neutron capture therapy. In the past, dose calculation was performed assuming a homogeneous mass density and elemental composition inside the tissue, regardless of the patient's age or sex. Studies have shown that the mass density varies with patient to patient, particularly for those that have undergone surgery or radiotherapy. A method to convert computed tomography numbers into mass density and elemental weights of tissues has been developed and applied in the dose calculation process using Monte Carlo codes. A recent study has shown the variation in the computed tomography number between different scanners for low- and high-density materials. PURPOSE The aim of this study is to investigate the effect of the elemental composition inside each calculation voxel on the dose calculation and the application of the stoichiometric CT number calibration method for boron neutron capture therapy planning. METHODS Monte Carlo simulation package Particle and Heavy Ion Transport code System was used for the dose calculation. Firstly, a homogeneous cubic phantom with the material set to ICRU soft tissue (four component), muscle, fat, and brain was modelled and the NeuCure BNCT system accelerator-based neutron source was used. The central axis depth dose distribution was simulated and compared between the four materials. Secondly, a treatment plan of the brain and the head and neck region was simulated using a dummy patient dataset. Three models were generated; (1) a model where only the fundamental materials were considered (simple model), a model where each voxel was assigned a mass density and elemental weight using (2) the Nakao20 model, and (3) the Schneider00 model. The irradiation conditions were kept the same between the different models (irradiation time and irradiation field size) and the near maximum (D1%) and mean dose to the organs at risk were calculated and compared. RESULTS A maximum percentage difference of approximately 5% was observed between the different materials for the homogeneous phantom. With the dummy patient plan, a large dose difference in the bone (greater than 12%) and region near the low-density material (mucosal membrane, 7%-11%) was found between the different models. CONCLUSIONS A stoichiometric CT number calibration method using the newly developed Nakao20 model was applied to BNCT dose calculation. The results indicate the importance of calibrating the CT number to elemental composition for each individual CT scanner for the purpose of BNCT dose calculation along with the consideration of heterogeneity of the material composition inside the defined region of interest.
Collapse
Affiliation(s)
- Naonori Hu
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Sennangun, Osaka, Japan
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan
| | - Minoru Nakao
- Hiroshima High-Precision Radiotherapy Cancer Center, Hiroshima, Japan
- Department of Radiation Oncology, Hiroshima University, Hiroshima, Japan
| | - Shuichi Ozawa
- Hiroshima High-Precision Radiotherapy Cancer Center, Hiroshima, Japan
- Department of Radiation Oncology, Hiroshima University, Hiroshima, Japan
| | - Takushi Takata
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Sennangun, Osaka, Japan
| | - Hiroki Tanaka
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Sennangun, Osaka, Japan
| | - Keiji Nihei
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan
- Department of Radiation Oncology, Osaka Medical and Pharmaceutical University Hospital, Takatsuki, Osaka, Japan
| | - Koji Ono
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan
| | - Minoru Suzuki
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Sennangun, Osaka, Japan
| |
Collapse
|
3
|
Kayama R, Tsujino K, Kawabata S, Fujikawa Y, Kashiwagi H, Fukuo Y, Hiramatsu R, Takata T, Tanaka H, Suzuki M, Hu N, Miyatake SI, Takami T, Wanibuchi M. Translational research of boron neutron capture therapy for spinal cord gliomas using rat model. Sci Rep 2024; 14:8265. [PMID: 38594281 PMCID: PMC11003979 DOI: 10.1038/s41598-024-58728-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2024] [Accepted: 04/02/2024] [Indexed: 04/11/2024] Open
Abstract
Boron neutron capture therapy (BNCT) is a type of targeted particle radiation therapy with potential applications at the cellular level. Spinal cord gliomas (SCGs) present a substantial challenge owing to their poor prognosis and the lack of effective postoperative treatments. This study evaluated the efficacy of BNCT in a rat SCGs model employing the Basso, Beattie, and Bresnahan (BBB) scale to assess postoperative locomotor activity. We confirmed the presence of adequate in vitro boron concentrations in F98 rat glioma and 9L rat gliosarcoma cells exposed to boronophenylalanine (BPA) and in vivo tumor boron concentration 2.5 h after intravenous BPA administration. In vivo neutron irradiation significantly enhanced survival in the BNCT group when compared with that in the untreated group, with a minimal BBB scale reduction in all sham-operated groups. These findings highlight the potential of BNCT as a promising treatment option for SCGs.
Collapse
Affiliation(s)
- Ryo Kayama
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki City, Osaka, Japan
| | - Kohei Tsujino
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki City, Osaka, Japan
| | - Shinji Kawabata
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki City, Osaka, Japan.
| | - Yoshiki Fujikawa
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki City, Osaka, Japan
| | - Hideki Kashiwagi
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki City, Osaka, Japan
| | - Yusuke Fukuo
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki City, Osaka, Japan
| | - Ryo Hiramatsu
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki City, Osaka, Japan
| | - Takashi Takata
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2 Asashiro-Nishi, Kumatori-Cho, Sennan-Gun, Osaka, Japan
| | - Hiroki Tanaka
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2 Asashiro-Nishi, Kumatori-Cho, Sennan-Gun, Osaka, Japan
| | - Minoru Suzuki
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2 Asashiro-Nishi, Kumatori-Cho, Sennan-Gun, Osaka, Japan
| | - Naonori Hu
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, 2-7 Daigakumachi, Takatsuki City, Osaka, Japan
| | - Shin-Ichi Miyatake
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, 2-7 Daigakumachi, Takatsuki City, Osaka, Japan
| | - Toshihiro Takami
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki City, Osaka, Japan
| | - Masahiko Wanibuchi
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki City, Osaka, Japan
| |
Collapse
|
4
|
Wang LS, Zhang LL, Liu SF, Hu N, Li JY, Hao SZ, Gong RZ. [The imaging presentations of the fallopian canal cerebrospinal fluid leaking]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2024; 59:147-151. [PMID: 38369793 DOI: 10.3760/cma.j.cn115330-20231124-00240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/20/2024]
Abstract
Objective: To summarize the imaging presentations of the fallopian canal cerebrospinal fluid leaking (FCCFL). Methods: The high resolution CT (HRCT)and MRI materials of 4 patients (4 ears) with FCCFL confirmed by surgery between August 2016 to November 2023 were retrospectively analyzed. Among these, there were 2 males and 2 females, their ages ranged from 6 to 69 years. Results: All of the FCCFL were unilateral, including 2 on the left and 2 on the right.Clinically, the patients with FCCFL suffered from clear nasal fluid flow, ear tightness, and hearing loss. On CT, all of the affected ears were depicted markedly dilatation of the proximal portion of fallopian canal(FC), the labyrinthine segment and geniculate fossa were involved in 4 cases, and involvement of tympanic segment in 1 case at the same time. The geniculate fossa in the affected side were significantly enlarged, protruding upwards into the tympanic cavity, with one case simultaneously involving the cochlea. On MRI, the hyposignal on T1WI and hypersignal on T2WI or water sequence like cerebrospinal fluid (CSF) were shown in the enlargement FC, without diffusion restriction, and non-enhancing with administration Gadolinium contrast.CSF-like signal effusion was shown in all of the affected tympanum, of which, the CSF-like signal effusion was demonstrated in the area along the superficial petrosal nerve, the right pterygopalatine fossa and the parapharyngeal space. The adjacent intracranial meninges were presented thickening in 3 cases. Conclusion: The imaging appearances of FCCFL present some characteristics:on HRCT, the proximal portions of the affected FC depicts markedly enlargement,especially the geniculate fossa.While they present CSF-like signal, no diffusion restriction, and no enhancement administration, Gadolinium contrast on MRI, accompanying the CSF-like signal effusion in the affected tympanum.
Collapse
Affiliation(s)
- L S Wang
- Department of Medical Imaging Center, Shandong Provincial ENT Hospital, Ji'nan 250023, China
| | - L L Zhang
- Department of Medical Imaging Center, Central Hospital Affiliated to Shandong First Medical University, Shandong University, Ji'nan 250013, China
| | - S F Liu
- Department of Medical Imaging Center, Shandong Provincial ENT Hospital, Ji'nan 250023, China
| | - N Hu
- Department of Medical Imaging Center, Shandong Provincial ENT Hospital, Ji'nan 250023, China
| | - J Y Li
- Department of Medical Imaging Center, Shandong Provincial ENT Hospital, Ji'nan 250023, China
| | - S Z Hao
- Department of Radiology, the People's Hospital of Zoucheng, Zoucheng 273599, China
| | - R Z Gong
- Department of Medical Imaging Center, Shandong Provincial ENT Hospital, Ji'nan 250023, China
| |
Collapse
|
5
|
Kakino R, Hu N, Tanaka H, Takeno S, Aihara T, Nihei K, Ono K. Out-of-field dosimetry using a validated PHITS model and computational phantom in clinical BNCT. Med Phys 2024; 51:1351-1363. [PMID: 38153111 DOI: 10.1002/mp.16916] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2023] [Revised: 10/03/2023] [Accepted: 12/14/2023] [Indexed: 12/29/2023] Open
Abstract
BACKGROUND The out-of-field radiation dose for boron neutron capture therapy (BNCT), which results from both neutrons and γ-rays, has not been extensively evaluated. To safely perform BNCT, the neutron and γ-ray distributions inside the treatment room and the whole-body dose should be evaluated during commissioning. Although, certain previous studies have evaluated the whole-body dose in the clinical research phase, no institution providing BNCT covered by health insurance has yet validated the neutron distribution inside the room and the whole-body dose. PURPOSE To validate the Monte Carlo model of the BNCT irradiation room extended for the whole-body region and evaluate organ-at-risk (OAR) doses using the validated model with a human-body phantom. METHODS First, thermal neutron distribution inside the entire treatment room was measured by placing Au samples on the walls of the treatment room. Second, neutron and gamma-ray dose-rate distributions inside a human-body water phantom were measured. Both lying and sitting positions were considered. Bare Au, Au covered by Cd (Au+Cd), In, Al, and thermoluminescent dosimeters were arranged at 11 points corresponding to locations of the OARs inside the phantom. After the irradiation, γ-ray peaks emitted from the samples were measured by a high-purity germanium detector. The measured counts were converted to the reaction rate per unit charge of the sample. These measurements were compared with results of simulations performed with the Particle and Heavy Ion Transport code System (PHITS). A male adult mesh-type reference computational phantom was used to evaluate OAR doses in the whole-body region. The relative biological effectiveness (RBE)-weighted doses and dose-volume histograms (DVHs) for each OAR were evaluated. The median dose (D50% ) and near-maximum dose (D2% ) were evaluated for 14 OARs in a 1-h-irradiation process. The evaluated RBE-weighted doses were converted to equivalent doses in 2 Gy fractions. RESULTS Experimental results within 60 cm from the irradiation center agreed with simulation results within the error bars except at ±20, 30 cm, and those over 70 cm corresponded within one digit. The experimental results of reaction rates or γ-ray dose rate for lying and sitting positions agreed well with the simulation results within the error bars at 8, 4, 11, 7 and 7, 4, 7, 6, 5, 6 out of 11 points, respectively, for Au, Au+Cd, In, Al, and TLD. Among the detectors, the discrepancies in reaction rates between experiment and simulation were most common for Au+Cd, but were observed randomly for measurement points (brain, lung, etc.). The experimental results of γ-ray dose rates were systematically lower than simulation results at abdomen and waist regions for both positions. Extending the PHITS model to the whole-body region resulted in higher doses for all OARs, especially 0.13 Gy-eq increase for D50% of the left salivary gland. CONCLUSION The PHITS model for clinical BNCT for the whole-body region was validated, and the OAR doses were then evaluated. Clinicians and medical physicists should know that the out-of-field radiation increases the OAR dose in the whole-body region.
Collapse
Affiliation(s)
- Ryo Kakino
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan
| | - Naonori Hu
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Osaka, Japan
| | - Hiroki Tanaka
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Osaka, Japan
| | - Satoshi Takeno
- Department of Radiation Oncology, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan
| | - Teruhito Aihara
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan
| | - Keiji Nihei
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan
- Department of Radiation Oncology, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan
| | - Koji Ono
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan
| |
Collapse
|
6
|
Maeda H, Nohtomi A, Hu N, Kakino R, Akita K, Ono K. Feasibility study of optical imaging of the boron-dose distribution by a liquid scintillator in a clinical boron neutron capture therapy field. Med Phys 2024; 51:509-521. [PMID: 37672219 DOI: 10.1002/mp.16727] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2023] [Revised: 08/06/2023] [Accepted: 08/23/2023] [Indexed: 09/07/2023] Open
Abstract
BACKGROUND Evaluation of the boron dose is essential for boron neutron capture therapy (BNCT). Nevertheless, a direct evaluation method for the boron-dose distribution has not yet been established in the clinical BNCT field. To date, even in quality assurance (QA) measurements, the boron dose has been indirectly evaluated from the thermal neutron flux measured using the activation method with gold foil or wire and an assumed boron concentration in the QA procedure. Recently, we successfully conducted optical imaging of the boron-dose distribution using a cooled charge-coupled device (CCD) camera and a boron-added liquid scintillator at the E-3 port facility of the Kyoto University Research Reactor (KUR), which supplies an almost pure thermal neutron beam with very low gamma-ray contamination. However, in a clinical accelerator-based BNCT facility, there is a concern that the boron-dose distribution may not be accurately extracted because the unwanted luminescence intensity, which is irrelevant to the boron dose is expected to increase owing to the contamination of fast neutrons and gamma rays. PURPOSE The purpose of this research was to study the validity of a newly proposed method using a boron-added liquid scintillator and a cooled CCD camera to directly observe the boron-dose distribution in a clinical accelerator-based BNCT field. METHOD A liquid scintillator phantom with 10 B was prepared by filling a small quartz glass container with a commercial liquid scintillator and boron-containing material (trimethyl borate); its natural boron concentration was 1 wt%. Luminescence images of the boron-neutron capture reaction were obtained in a water tank at several different depths using a CCD camera. The contribution of background luminescence, mainly due to gamma rays, was removed by subtracting the luminescence images obtained using another sole liquid scintillator phantom (natural boron concentration of 0 wt%) at each corresponding depth, and a depth profile of the boron dose with several discrete points was obtained. The obtained depth profile was compared with that of calculated boron dose, and those of thermal neutron flux which were experimentally measured or calculated using a Monte Carlo code. RESULTS The depth profile evaluated from the subtracted images indicated reasonable agreement with the calculated boron-dose profile and thermal neutron flux profiles, except for the shallow region. This discrepancy is thought to be due to the contribution of light reflected from the tank wall. The simulation results also demonstrated that the thermal neutron flux would be severely perturbed by the 10 B-containing phantom if a relatively larger container was used to evaluate a wide range of boron-dose distributions in a single shot. This indicates a trade-off between the luminescence intensity of the 10 B-added phantom and its perturbation effect on the thermal neutron flux. CONCLUSIONS Although a partial discrepancy was observed, the validity of the newly proposed boron-dose evaluation method using liquid-scintillator phantoms with and without 10 B was experimentally confirmed in the neutron field of an accelerator-based clinical BNCT facility. However, this study has some limitations, including the trade-off problem stated above. Therefore, further studies are required to address these limitations.
Collapse
Affiliation(s)
- Hideya Maeda
- Graduate School of Medical Sciences, Kyushu University, Fukuoka-shi, Fukuoka, Japan
| | - Akihiro Nohtomi
- Graduate School of Medical Sciences, Kyushu University, Fukuoka-shi, Fukuoka, Japan
| | - Naonori Hu
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Takatsuki-shi, Osaka, Japan
- Particle Radiation Oncology Research Center, Industrial Equipment Division, Kyoto University, Sennan-gun, Osaka, Japan
| | - Ryo Kakino
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Takatsuki-shi, Osaka, Japan
| | - Kazuhiko Akita
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Takatsuki-shi, Osaka, Japan
| | - Koji Ono
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Takatsuki-shi, Osaka, Japan
| |
Collapse
|
7
|
Hattori Y, Andoh T, Kawabata S, Hu N, Michiue H, Nakamura H, Nomoto T, Suzuki M, Takata T, Tanaka H, Watanabe T, Ono K. Proposal of recommended experimental protocols for in vitro and in vivo evaluation methods of boron agents for neutron capture therapy. J Radiat Res 2023; 64:859-869. [PMID: 37717596 PMCID: PMC10665309 DOI: 10.1093/jrr/rrad064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/16/2023] [Revised: 06/19/2023] [Accepted: 08/19/2023] [Indexed: 09/19/2023]
Abstract
Recently, boron neutron capture therapy (BNCT) has been attracting attention as a minimally invasive cancer treatment. In 2020, the accelerator-based BNCT with L-BPA (Borofalan) as its D-sorbitol complex (Steboronine®) for head and neck cancers was approved by Pharmaceutical and Medical Devices Agency for the first time in the world. As accelerator-based neutron generation techniques are being developed in various countries, the development of novel tumor-selective boron agents is becoming increasingly important and desired. The Japanese Society of Neutron Capture Therapy believes it is necessary to propose standard evaluation protocols at each stage in the development of boron agents for BNCT. This review summarizes recommended experimental protocols for in vitro and in vivo evaluation methods of boron agents for BNCT based on our experience with L-BPA approval.
Collapse
Affiliation(s)
- Yoshihide Hattori
- Research Center for BNCT, Osaka Metropolitan University, 1-1 Gakuen-cho, Nakaku, Sakai 599-8531, Japan
| | - Tooru Andoh
- Laboratory of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe 650-8586, Japan
| | - Shinji Kawabata
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki-shi, Osaka 569-8686, Japan
| | - Naonori Hu
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki-shi, Osaka 569-8686, Japan
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2, Asashiro-Nishi, Kumatori-cho, Sennan-gun 590-0494 Japan
| | - Hiroyuki Michiue
- Neutron Therapy Research Center, Okayama University, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan
| | - Hiroyuki Nakamura
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsuta-cho, Midori-ku, Yokohama 226-8503, Japan
| | - Takahiro Nomoto
- Department of Life Sciences, Graduate School of Arts and Sciences, The University of Tokyo, 3-8-1 Komaba, Meguro-ku, Tokyo 153-8902, Japan
| | - Minoru Suzuki
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2, Asashiro-Nishi, Kumatori-cho, Sennan-gun 590-0494 Japan
| | - Takushi Takata
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2, Asashiro-Nishi, Kumatori-cho, Sennan-gun 590-0494 Japan
| | - Hiroki Tanaka
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2, Asashiro-Nishi, Kumatori-cho, Sennan-gun 590-0494 Japan
| | - Tsubasa Watanabe
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2, Asashiro-Nishi, Kumatori-cho, Sennan-gun 590-0494 Japan
| | - Koji Ono
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki-shi, Osaka 569-8686, Japan
| |
Collapse
|
8
|
Hu N, Suzuki M, Masunaga SI, Kashino G, Kinashi Y, Chen YW, Liu Y, Uehara K, Mitsumoto T, Tanaka H, Ono K. Experimentally determined relative biological effectiveness of cyclotron-based epithermal neutrons designed for clinical BNCT: in vitro study. J Radiat Res 2023; 64:811-815. [PMID: 37607589 PMCID: PMC10516737 DOI: 10.1093/jrr/rrad056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/31/2023] [Revised: 06/07/2023] [Indexed: 08/24/2023]
Abstract
A neutron beam for boron neutron capture therapy (BNCT) of deep-seated tumours is designed to maintain a high flux of epithermal neutrons, while keeping the thermal and fast neutron component as low as possible. These neutrons (thermal and fast) have a high relative biological effectiveness in comparison with high energy photon beams used for conventional X-ray radiotherapy. In the past, neutrons for the purpose of BNCT were generated using nuclear reactors. However, there are various challenges that arise when installing a reactor in a hospital environment. From 2006, the Kyoto University Research Reactor Institute, in collaboration with Sumitomo Heavy Industries, began the development of an accelerator-based neutron source for clinical BNCT in a bid to overcome the shortcomings of a nuclear reactor-based neutron source. Following installation and beam performance testing, in vitro studies were performed to assess the biological effect of the neutron beam. Four different cell lines were prepared and irradiated using the accelerator-based neutron source. Following neutron and gamma ray irradiation, the survival curve for each cell line was calculated. The biological end point to determine the relative biological effectiveness (RBE) was set to 10% cell survival, and the D10 for each cell line was determined. The RBE of the accelerator-based neutron beam was evaluated to be 2.62.
Collapse
Affiliation(s)
- Naonori Hu
- Particle Radiation Oncology Research Center, Industrial Equipment Division, Kyoto University, 2, Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki-shi, Osaka 569-8686, Japan
| | - Minoru Suzuki
- Particle Radiation Oncology Research Center, Industrial Equipment Division, Kyoto University, 2, Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan
| | - Shin-ichiro Masunaga
- BNCT Research Center, Osaka Prefectural University, 1-1 Gakuen-cho, Naka-ku, Sakai, Osaka 599-8531, Japan
| | - Genro Kashino
- Advanced Medical Research Center, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara 634-8521, Japan
| | - Yuko Kinashi
- Particle Radiation Oncology Research Center, Industrial Equipment Division, Kyoto University, 2, Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan
| | - Yi-Wen Chen
- Department of Oncology, Taipei Veterans General Hospital, 201, Sec. 2, Shipai Rd., Beitou District, Taipei City, Taiwan 11217, Taiwan
| | - Yong Liu
- Department of Radiation Oncology, Shanghai General Hospital, 100 Haining Road, Hongkou District, Shanghai 200080, China
| | - Koki Uehara
- Stella Pharma Corporation, ORIX Kouraibashi Building, 3-2-7 Kouraibashi, Chuo-ku, Osaka 541-0043, Japan
| | - Toshinori Mitsumoto
- Industrial Equipment Division, Sumitomo Heavy Industries Ltd, 1-1, Osaki 2-chome, Shinagawa-ku, Tokyo 141-6025, Japan
| | - Hiroki Tanaka
- Particle Radiation Oncology Research Center, Industrial Equipment Division, Kyoto University, 2, Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan
| | - Koji Ono
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki-shi, Osaka 569-8686, Japan
| |
Collapse
|
9
|
Fujikawa Y, Fukuo Y, Nishimura K, Tsujino K, Kashiwagi H, Hiramatsu R, Nonoguchi N, Furuse M, Takami T, Hu N, Miyatake SI, Takata T, Tanaka H, Watanabe T, Suzuki M, Kawabata S, Nakamura H, Wanibuchi M. Evaluation of the Effectiveness of Boron Neutron Capture Therapy with Iodophenyl-Conjugated closo-Dodecaborate on a Rat Brain Tumor Model. Biology (Basel) 2023; 12:1240. [PMID: 37759639 PMCID: PMC10525593 DOI: 10.3390/biology12091240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/08/2023] [Revised: 09/12/2023] [Accepted: 09/13/2023] [Indexed: 09/29/2023]
Abstract
High-grade gliomas present a significant challenge in neuro-oncology because of their aggressive nature and resistance to current therapies. Boron neutron capture therapy (BNCT) is a potential treatment method; however, the boron used by the carrier compounds-such as 4-borono-L-phenylalanine (L-BPA)-have limitations. This study evaluated the use of boron-conjugated 4-iodophenylbutanamide (BC-IP), a novel boron compound in BNCT, for the treatment of glioma. Using in vitro drug exposure experiments and in vivo studies, we compared BC-IP and BPA, with a focus on boron uptake and retention characteristics. The results showed that although BC-IP had a lower boron uptake than BPA, it exhibited superior retention. Furthermore, despite lower boron accumulation in tumors, BNCT mediated by BC-IP showed significant survival improvement in glioma-bearing rats compared to controls (not treated animals and neutrons only). These results suggest that BC-IP, with its unique properties, may be an alternative boron carrier for BNCT. Further research is required to optimize this potential treatment modality, which could significantly contribute to advancing the treatment of high-grade gliomas.
Collapse
Affiliation(s)
- Yoshiki Fujikawa
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan; (Y.F.); (Y.F.); (K.T.); (H.K.); (R.H.); (N.N.); (M.F.); (T.T.); (M.W.)
| | - Yusuke Fukuo
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan; (Y.F.); (Y.F.); (K.T.); (H.K.); (R.H.); (N.N.); (M.F.); (T.T.); (M.W.)
| | - Kai Nishimura
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, Yokohama 226-8503, Japan; (K.N.); (H.N.)
| | - Kohei Tsujino
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan; (Y.F.); (Y.F.); (K.T.); (H.K.); (R.H.); (N.N.); (M.F.); (T.T.); (M.W.)
| | - Hideki Kashiwagi
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan; (Y.F.); (Y.F.); (K.T.); (H.K.); (R.H.); (N.N.); (M.F.); (T.T.); (M.W.)
| | - Ryo Hiramatsu
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan; (Y.F.); (Y.F.); (K.T.); (H.K.); (R.H.); (N.N.); (M.F.); (T.T.); (M.W.)
| | - Naosuke Nonoguchi
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan; (Y.F.); (Y.F.); (K.T.); (H.K.); (R.H.); (N.N.); (M.F.); (T.T.); (M.W.)
| | - Motomasa Furuse
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan; (Y.F.); (Y.F.); (K.T.); (H.K.); (R.H.); (N.N.); (M.F.); (T.T.); (M.W.)
| | - Toshihiro Takami
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan; (Y.F.); (Y.F.); (K.T.); (H.K.); (R.H.); (N.N.); (M.F.); (T.T.); (M.W.)
| | - Naonori Hu
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan; (N.H.); (S.-I.M.)
| | - Shin-Ichi Miyatake
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan; (N.H.); (S.-I.M.)
| | - Takushi Takata
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Osaka 590-0494, Japan; (T.T.); (H.T.); (T.W.); (M.S.)
| | - Hiroki Tanaka
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Osaka 590-0494, Japan; (T.T.); (H.T.); (T.W.); (M.S.)
| | - Tsubasa Watanabe
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Osaka 590-0494, Japan; (T.T.); (H.T.); (T.W.); (M.S.)
| | - Minoru Suzuki
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Osaka 590-0494, Japan; (T.T.); (H.T.); (T.W.); (M.S.)
| | - Shinji Kawabata
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan; (Y.F.); (Y.F.); (K.T.); (H.K.); (R.H.); (N.N.); (M.F.); (T.T.); (M.W.)
| | - Hiroyuki Nakamura
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, Yokohama 226-8503, Japan; (K.N.); (H.N.)
| | - Masahiko Wanibuchi
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan; (Y.F.); (Y.F.); (K.T.); (H.K.); (R.H.); (N.N.); (M.F.); (T.T.); (M.W.)
| |
Collapse
|
10
|
Monti Hughes A, Hu N. Optimizing Boron Neutron Capture Therapy (BNCT) to Treat Cancer: An Updated Review on the Latest Developments on Boron Compounds and Strategies. Cancers (Basel) 2023; 15:4091. [PMID: 37627119 PMCID: PMC10452654 DOI: 10.3390/cancers15164091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2023] [Revised: 07/27/2023] [Accepted: 07/31/2023] [Indexed: 08/27/2023] Open
Abstract
Boron neutron capture therapy (BNCT) is a tumor-selective particle radiotherapy. It combines preferential boron accumulation in tumors and neutron irradiation. The recent initiation of BNCT clinical trials employing hospital-based accelerators rather than nuclear reactors as the neutron source will conceivably pave the way for new and more numerous clinical trials, leading up to much-needed randomized trials. In this context, it would be interesting to consider the implementation of new boron compounds and strategies that will significantly optimize BNCT. With this aim in mind, we analyzed, in this review, those articles published between 2020 and 2023 reporting new boron compounds and strategies that were proved therapeutically useful in in vitro and/or in vivo radiobiological studies, a critical step for translation to a clinical setting. We also explored new pathologies that could potentially be treated with BNCT and newly developed theranostic boron agents. All these radiobiological advances intend to solve those limitations and questions that arise during patient treatment in the clinical field, with BNCT and other therapies. In this sense, active communication between clinicians, radiobiologists, and all disciplines will improve BNCT for cancer patients, in a cost- and time-effective way.
Collapse
Affiliation(s)
- Andrea Monti Hughes
- Radiation Pathology Division, Department Radiobiology, National Atomic Energy Commission, San Martín, Buenos Aires B1650KNA, Argentina
- National Scientific and Technical Research Council, Ciudad Autónoma de Buenos Aires C1425FQB, Argentina
| | - Naonori Hu
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan;
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Osaka 590-0494, Japan
| |
Collapse
|
11
|
Burden AD, Okubo Y, Zheng M, Thaçi D, van de Kerkhof P, Hu N, Quaresma M, Thoma C, Choon SE. Efficacy of spesolimab for the treatment of generalized pustular psoriasis flares across pre-specified patient subgroups in the Effisayil 1 study. Exp Dermatol 2023; 32:1279-1283. [PMID: 37140190 DOI: 10.1111/exd.14824] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2023] [Revised: 04/13/2023] [Accepted: 04/19/2023] [Indexed: 05/05/2023]
Abstract
Effisayil 1 was a multicentre, randomized, double-blind, placebo-controlled study of the anti-interleukin (IL)-36 receptor monoclonal antibody, spesolimab, in patients presenting with a generalized pustular psoriasis (GPP) flare. Previously published data from this study revealed that within 1 week, rapid pustular and skin clearance were observed in patients receiving spesolimab versus placebo. In this pre-specified subgroup analysis, the efficacy of spesolimab was evaluated according to patient demographic and clinical characteristics at baseline in patients receiving spesolimab (n = 35) or placebo (n = 18) on Day 1. Efficacy was by assessed by achievement of primary endpoint (Generalized Pustular Psoriasis Physician Global Assessment [GPPGA] pustulation subscore of 0 at Week 1) and key secondary endpoint (GPPGA total score of 0 or 1 at Week 1). Safety was assessed at Week 1. Spesolimab was found to be efficacious and had a consistent and favourable safety profile in patients presenting with a GPP flare, regardless of patient demographics and clinical characteristics at baseline.
Collapse
Affiliation(s)
- A D Burden
- School of Infection and Immunity, University of Glasgow, Glasgow, UK
| | - Y Okubo
- Department of Dermatology, Tokyo Medical University, Tokyo, Japan
| | - M Zheng
- Department of Dermatology, Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China
| | - D Thaçi
- Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany
| | - P van de Kerkhof
- Department of Dermatology, Radboud University, Nijmegen, The Netherlands
| | - N Hu
- Boehringer Ingelheim (China) Investment Co., Ltd, Shanghai, China
| | - M Quaresma
- Boehringer Ingelheim International GmbH, Ingelheim, Germany
| | - C Thoma
- Boehringer Ingelheim International GmbH, Biberach, Germany
| | - S E Choon
- Department of Dermatology, Hospital Sultanah Aminah, Clinical School Johor Bahru, Monash University Malaysia, Subang Jaya, Malaysia
| |
Collapse
|
12
|
Sasaki A, Hu N, Matsubayashi N, Takata T, Sakurai Y, Suzuki M, Tanaka H. Development of optimization method for uniform dose distribution on superficial tumor in an accelerator-based boron neutron capture therapy system. J Radiat Res 2023; 64:602-611. [PMID: 37100599 DOI: 10.1093/jrr/rrad020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/21/2022] [Revised: 12/05/2022] [Indexed: 05/27/2023]
Abstract
To treat superficial tumors using accelerator-based boron neutron capture therapy (ABBNCT), a technique was investigated, based on which, a single-neutron modulator was placed inside a collimator and was irradiated with thermal neutrons. In large tumors, the dose was reduced at their edges. The objective was to generate a uniform and therapeutic intensity dose distribution. In this study, we developed a method for optimizing the shape of the intensity modulator and irradiation time ratio to generate a uniform dose distribution to treat superficial tumors of various shapes. A computational tool was developed, which performed Monte Carlo simulations using 424 different source combinations. We determined the shape of the intensity modulator with the highest minimum tumor dose. The homogeneity index (HI), which evaluates uniformity, was also derived. To evaluate the efficacy of this method, the dose distribution of a tumor with a diameter of 100 mm and thickness of 10 mm was evaluated. Furthermore, irradiation experiments were conducted using an ABBNCT system. The thermal neutron flux distribution outcomes that have considerable impacts on the tumor's dose confirmed a good agreement between experiments and calculations. Moreover, the minimum tumor dose and HI improved by 20 and 36%, respectively, compared with the irradiation case wherein a single-neutron modulator was used. The proposed method improves the minimum tumor volume and uniformity. The results demonstrate the method's efficacy in ABBNCT for the treatment of superficial tumors.
Collapse
Affiliation(s)
- Akinori Sasaki
- Graduate School of Engineering, Kyoto University, Kyoto University Katsura Campus, Kyoto Nishikyo-ku, Kyoto 615-8246, Japan
| | - Naonori Hu
- Particle Radiation Oncology Research Center, Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2-Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan
- Kansai BNCT Medical Center, Educational Foundation of Osaka Medical and Pharmaceutical University, Daigakumachi, Takatsuki, Osaka 569-0801, Japan
| | - Nishiki Matsubayashi
- Graduate School of Engineering, Kyoto University, Kyoto University Katsura Campus, Kyoto Nishikyo-ku, Kyoto 615-8246, Japan
| | - Takushi Takata
- Particle Radiation Oncology Research Center, Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2-Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan
| | - Yoshinori Sakurai
- Particle Radiation Oncology Research Center, Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2-Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan
| | - Minoru Suzuki
- Particle Radiation Oncology Research Center, Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2-Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan
| | - Hiroki Tanaka
- Particle Radiation Oncology Research Center, Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2-Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan
| |
Collapse
|
13
|
Li J, Sun L, Hu N, Li L, Song G, Xu H, Xu T, Cheng Y, Xiao L, Wang L, Gong R, Li C. A Novel MR Imaging Sequence of 3D-ZOOMit Real Inversion-Recovery Imaging Improves Endolymphatic Hydrops Detection in Patients with Ménière Disease. AJNR Am J Neuroradiol 2023; 44:595-601. [PMID: 37105675 PMCID: PMC10171393 DOI: 10.3174/ajnr.a7842] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2022] [Accepted: 03/08/2023] [Indexed: 04/29/2023]
Abstract
BACKGROUND AND PURPOSE The detection rate of premortem MR imaging endolymphatic hydrops is lower than that of postmortem endolymphatic hydrops in Ménière disease, indicating that current MR imaging techniques may underestimate endolymphatic hydrops. Therefore, we prospectively investigated whether a novel high-resolution MR imaging technique, the 3D zoomed imaging technique with parallel transmission real inversion-recovery (3D-ZOOMit real IR), would improve the detection of endolymphatic hydrops compared with conventional 3D TSE inversion-recovery with real reconstruction. MATERIALS AND METHODS Fifty patients with definite unilateral Ménière disease were enrolled and underwent 3D-ZOOMit real IR and 3D TSE inversion-recovery with real reconstruction 6 hours after IV gadolinium injection. The endo- and perilymph spaces were scored separately. The contrast-to-noise ratio, SNR, and signal intensity ratio of the 2 sequences were respectively calculated and compared. The presence of endolymphatic hydrops was evaluated. RESULTS The endolymphatic space in the cochlea and vestibule was better visualized with 3D-ZOOMit real IR than with conventional 3D TSE inversion-recovery with real reconstruction (P < .001). There were differences between the 2 sequences in the evaluation of no cochlear hydrops and cochlear hydrops (both, P < .017). All contrast-to-noise ratio, SNR, and signal intensity ratio values of 3D-ZOOMit real IR images were statistically higher than those of conventional 3D TSE inversion-recovery with real reconstruction (all, P < .001). CONCLUSIONS The 3D-ZOOMit real IR sequences are superior to conventional 3D TSE inversion-recovery with real reconstruction sequences in visualizing the endolymphatic space, detecting endolymphatic hydrops, and discovering contrast permeability.
Collapse
Affiliation(s)
- J Li
- From the Departments of Radiology (J.L., L.S., N.H., T.X., L.W., R.G.)
| | - L Sun
- From the Departments of Radiology (J.L., L.S., N.H., T.X., L.W., R.G.)
| | - N Hu
- From the Departments of Radiology (J.L., L.S., N.H., T.X., L.W., R.G.)
| | - L Li
- Medical Service (L.L.), Shandong Provincial ENT Hospital, Shandong University, Jinan, China
| | - G Song
- Department of Radiology (G.S.), Shandong Province Qianfoshan Hospital, Jinan, China
| | - H Xu
- Department of Radiology (H.X., R.G., C.L.)
| | - T Xu
- From the Departments of Radiology (J.L., L.S., N.H., T.X., L.W., R.G.)
| | - Y Cheng
- Siemens Healthineers Digital Technology (Shanghai) Co. Ltd (Y.C.), Shanghai, China
| | - L Xiao
- MR Scientific Marketing (L.X.), Diagnostic Imaging, Siemens Healthineers Ltd, Shanghai, China
| | - L Wang
- From the Departments of Radiology (J.L., L.S., N.H., T.X., L.W., R.G.)
| | - R Gong
- From the Departments of Radiology (J.L., L.S., N.H., T.X., L.W., R.G.)
- Department of Radiology (H.X., R.G., C.L.)
- Gong Ruozhen Innovation Studio (R.G.), Shandong Provincial Hospital, Shandong University, Jinan, China
| | - C Li
- Department of Radiology (H.X., R.G., C.L.)
| |
Collapse
|
14
|
Nojiri M, Takata T, Hu N, Sakurai Y, Suzuki M, Tanaka H. Development and evaluation of dose calculation algorithm with a combination of Monte Carlo and point-kernel methods for boron neutron capture therapy. Biomed Phys Eng Express 2023; 9. [PMID: 37021631 DOI: 10.1088/2057-1976/acc33c] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2022] [Accepted: 03/10/2023] [Indexed: 04/07/2023]
Abstract
We developed a 'hybrid algorithm' that combines the Monte Carlo (MC) and point-kernel methods for fast dose calculation in boron neutron capture therapy. The objectives of this study were to experimentally verify the hybrid algorithm and to verify the calculation accuracy and time of a 'complementary approach' adopting both the hybrid algorithm and the full-energy MC method. In the latter verification, the results were compared with those obtained using the full-energy MC method alone. In the hybrid algorithm, the moderation process of neutrons is simulated using only the MC method, and the thermalization process is modeled as a kernel. The thermal neutron fluxes calculated using only this algorithm were compared with those measured in a cubic phantom. In addition, a complementary approach was used for dose calculation in a geometry simulating the head region, and its computation time and accuracy were verified. The experimental verification indicated that the thermal neutron fluxes calculated using only the hybrid algorithm reproduced the measured values at depths exceeding a few centimeters, whereas they overestimated those at shallower depths. Compared with the calculation using only the full-energy MC method, the complementary approach reduced the computation time by approximately half, maintaining nearly same accuracy. When focusing on the calculation only using the hybrid algorithm only for the boron dose attributed to the reaction of thermal neutrons, the computation time was expected to reduce by 95% compared with the calculation using only the full-energy MC method. In conclusion, modeling the thermalization process as a kernel was effective for reducing the computation time.
Collapse
Affiliation(s)
- Mai Nojiri
- Department of Nuclear Engineering, Graduate School of Engineering, Kyoto University, Kyoutodaigaku-Katsura, Kyoto, Japan
| | - Takushi Takata
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Kumatori-cho, Osaka, Japan
| | - Naonori Hu
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Kumatori-cho, Osaka, Japan
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Takatsuki, Japan
| | - Yoshinori Sakurai
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Kumatori-cho, Osaka, Japan
| | - Minoru Suzuki
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Kumatori-cho, Osaka, Japan
| | - Hiroki Tanaka
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Kumatori-cho, Osaka, Japan
| |
Collapse
|
15
|
Forde P, Spicer J, Girard N, Provencio M, Lu S, Wang C, Awad M, Mitsudomi T, Felip E, Swanson S, Saylors G, Chen KN, Tanaka F, Tran P, Hu N, Cai J, Bushong J, Neely J, Balli D, Broderick S. 84O Neoadjuvant nivolumab (N) + platinum-doublet chemotherapy (C) for resectable NSCLC: 3-y update from CheckMate 816. J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00338-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/04/2023]
|
16
|
Matsubayashi N, Hu N, Takata T, Sasaki A, Mukawa T, Suga K, Sakurai Y, Tanaka H. Characteristics of optically stimulated luminescent dosimeter of beryllium oxide in BNCT irradiation field. RADIAT MEAS 2023. [DOI: 10.1016/j.radmeas.2023.106900] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
17
|
Dong M, Hu N, Hua Y, Xu X, Kandadi M, Guo R, Jiang S, Nair S, Hu D, Ren J. Erratum to: “Chronic Akt activation attenuated lipopolysaccharide-induced cardiac dysfunction via Akt/GSK3β-dependent inhibition of apoptosis and ER stress” [Biochim. Biophys. Acta. 1832(6) 2013 Jun; 848–63. doi:10.1016/j.bbadis.2013.02.023. Epub 2013 Mar 6.PMID: 23474308]. Biochim Biophys Acta Mol Basis Dis 2023; 1869:166567. [DOI: 10.1016/j.bbadis.2022.166567] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
18
|
Hu N, Tanaka H, Akita K, Kakino R, Aihara T, Nihei K, Ono K. Accelerator based epithermal neutron source for clinical boron neutron capture therapy. JNR 2022. [DOI: 10.3233/jnr-220037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
The world’s first accelerator based epithermal neutron source for clinical boron neutron capture therapy (BNCT) was designed, developed, and commissioned between 2008 and 2010 by Sumitomo Heavy Industries in collaboration with Kyoto University at the Kyoto University Institute for Integrated Radiation and Nuclear Science. The accelerator system is cyclotron-based and accelerates a proton up to an energy of approximately 30 MeV. The proton strikes a beryllium target, which produces fast neutrons that traverse a beam shaping assembly composed of a combination of lead, iron, aluminum, and calcium fluoride to reduce the neutron energy down to the epithermal range (∼10 keV) suitable for BNCT. The system is designed to produce an epithermal neutron flux of up to 1.4 × 10 9 n · cm − 2 · s − 1 (exiting from the moderator of a 12 cm diameter collimator) with a proton current of 1 mA. In 2017, the same type of accelerator was installed at the Kansai BNCT Medical Center and in March 2020 the system received medical device approval in Japan (Sumitomo Heavy Industries, NeuCure® BNCT system). Soon after, BNCT for unresectable, locally advanced, and recurrent carcinoma of the head and neck region was approved by the Japanese government for reimbursement covered by the national health insurance system.
Collapse
Affiliation(s)
- Naonori Hu
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Japan
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Japan
| | - Hiroki Tanaka
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Japan
| | - Kazuhiko Akita
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Japan
| | - Ryo Kakino
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Japan
| | - Teruhito Aihara
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Japan
| | - Keiji Nihei
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Japan
| | - Koji Ono
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Japan
| |
Collapse
|
19
|
Sasaki A, Hu N, Takata T, Matsubayashi N, Sakurai Y, Suzuki M, Tanaka H. Intensity-modulated irradiation for superficial tumors by overlapping irradiation fields using intensity modulators in accelerator-based BNCT. J Radiat Res 2022; 63:866-873. [PMID: 36149023 PMCID: PMC9726706 DOI: 10.1093/jrr/rrac052] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/12/2022] [Revised: 07/12/2022] [Indexed: 05/12/2023]
Abstract
The distribution of the thermal neutron flux has a significant impact on the treatment efficacy. We developed an irradiation method of overlapping irradiation fields using intensity modulators for the treatment of superficial tumors with the aim of expanding the indications for accelerator-based boron neutron capture therapy (BNCT). The shape of the intensity modulator was determined and Monte Carlo simulations were carried out to determine the uniformity of the resulting thermal neutron flux distribution. The intensity modulators were then fabricated and irradiation tests were conducted, which resulted in the formation of a uniform thermal neutron flux distribution. Finally, an evaluation of the tumor dose distribution showed that when two irradiation fields overlapped, the minimum tumor dose was 27.4 Gy-eq, which was higher than the tumor control dose of 20 Gy-eq. Furthermore, it was found that the uniformity of the treatment was improved 47% as compared to the treatment that uses a single irradiation field. This clearly demonstrates the effectiveness of this technique and the possibility of expanding the indications to superficially located tumors.
Collapse
Affiliation(s)
- Akinori Sasaki
- Graduate School of Engineering, Kyoto University, Kyoto University Katsura, Kyoto Nishikyo-ku, Kyoto 615-8246, Japan
| | - Naonori Hu
- Particle Radiation Oncology Research Center, Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2-Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan
- Kansai BNCT Medical Center, Educational Foundation of Osaka Medical and Pharmaceutical University, Daigakumachi, Takatsuki, Osaka 569-0801, Japan
| | - Takushi Takata
- Particle Radiation Oncology Research Center, Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2-Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan
| | - Nishiki Matsubayashi
- Graduate School of Engineering, Kyoto University, Kyoto University Katsura, Kyoto Nishikyo-ku, Kyoto 615-8246, Japan
| | - Yoshinori Sakurai
- Particle Radiation Oncology Research Center, Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2-Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan
| | - Minoru Suzuki
- Particle Radiation Oncology Research Center, Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2-Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan
| | - Hiroki Tanaka
- Corresponding author. Particle Radiation Oncology Research Center, Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2-Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan, Tel: +81-72-451-2468;
| |
Collapse
|
20
|
Isohashi K, Kanai Y, Aihara T, Hu N, Fukushima K, Baba I, Hirokawa F, Kakino R, Komori T, Nihei K, Hatazawa J, Ono K. Exploration of the threshold SUV for diagnosis of malignancy using 18F-FBPA PET/CT. Eur J Hybrid Imaging 2022; 6:35. [DOI: 10.1186/s41824-022-00156-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2022] [Accepted: 11/09/2022] [Indexed: 12/05/2022] Open
Abstract
Abstract
Background
The goal of the study was to evaluate the diagnostic ability of 18F-FBPA PET/CT for malignant tumors. Findings from 18F-FBPA and 18F-FDG PET/CT were compared with pathological diagnoses in patients with malignant tumors or benign lesions.
Methods
A total of 82 patients (45 males, 37 females; median age, 63 years; age range, 20–89 years) with various types of malignant tumors or benign lesions, such as inflammation and granulomas, were examined by 18F-FDG and 18F-FBPA PET/CT. Tumor uptake of FDG or FBPA was quantified using the maximum standardized uptake value (SUVmax). The final diagnosis was confirmed by cytopathology or histopathological findings of the specimen after biopsy or surgery. A ROC curve was constructed from the SUVmax values of each PET image, and the area under the curve (AUC) and cutoff values were calculated.
Results
The SUVmax for 18F-FDG PET/CT did not differ significantly for malignant tumors and benign lesions (10.9 ± 6.3 vs. 9.1 ± 2.7 P = 0.62), whereas SUVmax for 18F-FBPA PET/CT was significantly higher for malignant tumors (5.1 ± 3.0 vs. 2.9 ± 0.6, P < 0.001). The best SUVmax cutoffs for distinguishing malignant tumors from benign lesions were 11.16 for 18F-FDG PET/CT (sensitivity 0.909, specificity 0.390) and 3.24 for 18F-FBPA PET/CT (sensitivity 0.818, specificity 0.753). ROC analysis showed significantly different AUC values for 18F-FDG and 18F-FBPA PET/CT (0.547 vs. 0.834, p < 0.001).
Conclusion
18F-FBPA PET/CT showed superior diagnostic ability over 18F-FDG PET/CT in differential diagnosis of malignant tumors and benign lesions. The results of this study suggest that 18F-FBPA PET/CT diagnosis may reduce false-positive 18F-FDG PET/CT diagnoses.
Collapse
|
21
|
Tsujino K, Kawabata S, Kashiwagi H, Yoshimura K, Kayama R, Fukuo Y, Kanemitsu T, Hiramatsu R, Hu N, Miyatake SI, Nishimura K, Takata T, Tanaka H, Suzuki M, Nakamura H, Wanibuchi M. ET-4 BASIC RESEARCH OF BORON NEUTRON CAPTURE THERAPY USING A NOVEL BORON COMPOUND TARGETED TO INTEGRIN. Neurooncol Adv 2022. [PMCID: PMC9719331 DOI: 10.1093/noajnl/vdac167.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022] Open
Abstract
Abstract
Background
Boron neutron capture therapy (BNCT) is a particle radiation modality capable of selectively destroying tumor cells. The most commonly used boron compound for BNCT is boronphenylalanine (BPA). BPA is taken up into the tumor cell via the L-type aminoacid transporter (LAT-1). However, there are some BPA-refractory situations. Therefore, a novel boron compound is expected to improve the therapeutic performance of BNCT. We focused on integrinαvβ3, which is overexpressed in malignant gliomas as in many cancer cells, and have developed cRGD-MID-AC, a conjugate of cyclic RGD (cRGD), which selectively inhibited integrinαvβ3, and MID-AC, which we have already reported as effective on BNCT as BPA as a boron compound in F98 rat glioma models. We evaluated the efficacy of BNCT using this novel compound.Methods: F98 glioma cells were exposed to BPA, cRGD-MID-AC, and cRGD-MID for cellular uptake and neutron irradiation experiment. Intracellular boron concentrations and compound biological effectiveness (CBE) for each boron compound was calculated. After intravenous administration (i.v.) of cRGD-MID-AC or BPA, the biodistribution of boron compounds was measured and neutron irradiation experiment were performed in F98 rat glioma models.
Results
Intracellular boron concentrations of BPA and cRGD-MID-AC were increased gradually at all exposed time, and CBE for cRGD-MID-AC was comparable to that for BPA. In cRGD-MID-AC, the boron concentration in the tumor was the highest at 8 h after i.v. and tended to be retained longer at 24h. In vivo neutron irradiation experiment, long-term survival was observed only in the group irradiated 8 h after cRGD-MID-AC i.v.. These experiments suggest that cRGD-MID-AC has sufficient cell-killing effect and may be more effective in vivo.
Conclusion
cRGD-MID-AC has a tumor accumulation mechanism different from that of BPA, and could be an effective boron carrier in BNCT for malignant gliomas.
Collapse
Affiliation(s)
- Kohei Tsujino
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University , Takatsuki , Japan
| | - Shinji Kawabata
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University , Takatsuki , Japan
| | - Hideki Kashiwagi
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University , Takatsuki , Japan
| | - Kohei Yoshimura
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University , Takatsuki , Japan
| | - Ryo Kayama
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University , Takatsuki , Japan
| | - Yusuke Fukuo
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University , Takatsuki , Japan
| | - Takuya Kanemitsu
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University , Takatsuki , Japan
| | - Ryo Hiramatsu
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University , Takatsuki , Japan
| | - Naonori Hu
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University
| | | | - Kai Nishimura
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology
| | - Takushi Takata
- Institute for Integrated Radiation and Nuclear Science, Kyoto University
| | - Hiroki Tanaka
- Institute for Integrated Radiation and Nuclear Science, Kyoto University
| | - Minoru Suzuki
- Institute for Integrated Radiation and Nuclear Science, Kyoto University
| | - Hiroyuki Nakamura
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology
| | - Masahiko Wanibuchi
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University , Takatsuki , Japan
| |
Collapse
|
22
|
Kawabata S, Tsujino K, Kashiwagi H, Yoshimura K, Hiramatsu R, Nonoguchi N, Furuse M, Takami T, Hu N, Ono K, Miyatake SI, Wanibuchi M. RT-6 POTENTIAL AND PROSPECTS OF BORON NEUTRON CAPTURE THERAPY USING A COMBINATION OF MULTIPLE BORON AGENTS. Neurooncol Adv 2022. [DOI: 10.1093/noajnl/vdac167.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022] Open
Abstract
Abstract
Boron neutron capture therapy (BNCT) is a particle therapy that can target tumors at the cellular level. BNCT has been developed for the treatment of malignant gliomas with widely infiltrated tumors, but as the indication for BNCT was expanded to include the whole body, the focus shifted to borophalan-10B (BPA), which is based on the essential amino acid phenylalanine, as a candidate agent. We started BNCT for brain tumors in 2002 with a protocol combining two compounds (BPA, BSH) that had been clinically used, but later, with the development of an accelerator-based system, we conducted a clinical study of a single agent of BPA with a modified administration protocol in a nuclear reactor. In this report, we analyze the clinical studies of BNCT for recurrent malignant glioma using the reactor as a neutron source, and discuss the possibility of BNCT using multiple drugs in combination. The median survival with BSH+BPA was 11.0 months (n=29) overall, and the MST with BPA alone was 11.1 months (n=24), with similar results for BPA alone. The blood boron levels at the time of irradiation were 46.3 and 27.3 μg/ml, respectively, which were higher with the addition of BSH. The irradiation doses converted to X-rays (Gy) equivalent were calculated to be 69 and 76 Gy-Eq for the maximum tumor, 37 and 40 Gy-Eq for the minimum, and 10.9 and 10.5 Gy-Eq for the normal brain, respectively. The biological effectiveness ratios for tumor and normal tissue from neutron capture reactions with boron compounds and tissue boron concentrations were factored into these calculations, and since BPA and BSH have different target systems (BPA in the infiltration zone and BSH in the contrast zone, respectively), we believe that their combined use may improve therapeutic efficacy and attenuate adverse events.
Collapse
Affiliation(s)
- Shinji Kawabata
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University , Osaka , Japan
| | - Kohei Tsujino
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University , Osaka , Japan
| | - Hideki Kashiwagi
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University , Osaka , Japan
| | - Kohei Yoshimura
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University , Osaka , Japan
| | - Ryo Hiramatsu
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University , Osaka , Japan
| | - Naosuke Nonoguchi
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University , Osaka , Japan
| | - Motomasa Furuse
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University , Osaka , Japan
| | - Toshihiro Takami
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University , Osaka , Japan
| | - Naonori Hu
- Kansai BNCT Medical Center, Osaka Medical College , Osaka , Japan
| | - Koji Ono
- Kansai BNCT Medical Center, Osaka Medical College , Osaka , Japan
| | | | - Masahiko Wanibuchi
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University , Osaka , Japan
| |
Collapse
|
23
|
Du YL, Hu N, Wang K, Cui RL, Zhang HJ, Ke Y, Pan KF, Duan LP. [The correlation between reflux esophagitis and Helicobacter pylori infection based on natural population]. Zhonghua Nei Ke Za Zhi 2022; 61:1330-1335. [PMID: 36456513 DOI: 10.3760/cma.j.cn112138-20220214-00107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/17/2023]
Abstract
Objective: Reflux esophagitis (RE) may be negatively correlated with Helicobacter pylori (H. pylori) infection, but the conclusion and relevant mechanism is still controversial. This study proposed to explore the correlation between RE and H. pylori infection based on natural population. Methods: From July 2013 to December 2014, 3 940 residents aged 40-69 years were recruited in Linqu County of Shandong Province and Hua County of Henan Province by the whole sampling method. All the subjects underwent gastroscopy, and gastric mucosa biopsy specimens were collected for pathological diagnosis and Warthin-Starry (WS) staining to identify H. pylori infection. Venous blood samples of some subjects were collected for H. pylori immunoglobulin G (H. pylori-IgG) detection. Also, demographic and sociological data were collected. Chi-square test and logistic regression were used to analyze the correlation between RE and H. pylori infection. Results: A total of 359 cases of RE were detected. Excluding RE and other upper gastrointestinal organic diseases, 3 382 cases were considered as controls. Chi-square test showed that WS staining positive rate in RE group was significantly lower than that in control group (P=0.023), but there was no significant difference in the positive rate of H. pylori-IgG between the two groups (P=0.281). There were significant differences between RE group and control group in gender composition, age, body mass index (BMI), smoking, alcohol consumption, education level and mucosal active inflammation. Multivariate regression analysis showed that RE was negatively correlated with gastric mucosa active inflammation [OR=0.754 (95%CI 0.600-0.949), P=0.016], and positively correlated with male [OR=4.231 (95%CI 3.263-5.486), P<0.001], age ≥60 years, BMI≥24 kg/m2 [OR=1.540 (95%CI 1.220-1.945), P<0.001]. Compared to those aged 40-49 years and 50-59 years, the odds ratio (OR) of RE in these aged ≥60 years were 1.566 (95%CI 1.144-2.143, P=0.005) and 1.405 (95%CI 1.093-1.805, P=0.008). Conclusion: RE is more closely related to H. pylori present infection. Multivariate analysis showed that RE is negatively correlated with active inflammation of gastric mucosa caused by H. pylori infection, and positively correlated with male, overweight and aged ≥60 years.
Collapse
Affiliation(s)
- Y L Du
- Department of Gastroenterology, Peking University Third Hospital, Beijing 100191, China
| | - N Hu
- Department of Gastroenterology, Peking University Third Hospital, Beijing 100191, China
| | - K Wang
- Department of Gastroenterology, Peking University Third Hospital, Beijing 100191, China
| | - R L Cui
- Department of Gastroenterology, Peking University Third Hospital, Beijing 100191, China
| | - H J Zhang
- Department of Gastroenterology, Peking University Third Hospital, Beijing 100191, China
| | - Y Ke
- Department of Genetics, Peking University Cancer Hospital, Beijing 100142, China
| | - K F Pan
- Department of Epidemiology, Peking University Cancer Hospital, Beijing 100142, China
| | - L P Duan
- Department of Gastroenterology, Peking University Third Hospital, Beijing 100191, China
| |
Collapse
|
24
|
Hu N, Tanaka H, Ono K. Design of a filtration system to improve the dose distribution of an accelerator-based neutron capture therapy system. Med Phys 2022; 49:6609-6621. [PMID: 35941788 PMCID: PMC9804710 DOI: 10.1002/mp.15864] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2021] [Revised: 06/16/2022] [Accepted: 07/07/2022] [Indexed: 01/09/2023] Open
Abstract
PURPOSE The aim of this study is to design and evaluate a neutron filtration system to improve the dose distribution of an accelerator-based neutron capture therapy system. METHODS An LiF-sintered plate composed of 99%-enriched 6 Li was utilized to filter out low-energy neutrons to increase the average neutron energy at the beam exit. A 5-mm thick filter to fit inside a 12-cm diameter circular collimator was manufactured, and experimental measurements were performed to measure the thermal neutron flux and gamma-ray dose rate inside a water phantom. The experimental measurements were compared with the Monte Carlo simulation, particle, and heavy ion transport code system. Following the experimental verification, three filter designs were modeled, and the thermal neutron flux and the biologically weighted dose distribution inside a phantom were simulated. Following the phantom simulation, a dummy patient CT dataset was used to simulate a boron neutron capture therapy (BNCT) irradiation of the brain. A mock tumor located at 4, 6, 8 cm along the central axis and 4-cm off-axis was set, and the dose distribution was simulated for a maximum total biologically weighted brain dose of 12.5 Gy with a beam entering from the vertex. RESULTS All three filters improved the beam penetration of the accelerator-based neutron source. Filter design C was found to be the most suitable filter, increasing the advantage depth from 9.1 to 9.9 cm. Compared with the unfiltered beam, the mean weighted dose in the tumor located at a depth of 8 cm along the beam axis was increased by ∼25%, and 34% for the tumor located at a depth of 8 cm and off-axis by 4 cm. CONCLUSION A neutron filtration system for an accelerator-based BNCT system was investigated using Monte Carlo simulation. The proposed filter design significantly improved the dose distribution for the treatment of deep targets in the brain.
Collapse
Affiliation(s)
- Naonori Hu
- Kansai BNCT Medical CenterOsaka Medical and Pharmaceutical UniversityOsakaJapan,Particle Radiation Oncology Research CenterKyoto UniversityInstitute for Integrated Radiation and Nuclear ScienceOsakaJapan
| | - Hiroki Tanaka
- Particle Radiation Oncology Research CenterKyoto UniversityInstitute for Integrated Radiation and Nuclear ScienceOsakaJapan
| | - Koji Ono
- Kansai BNCT Joint Clinical InstituteOsaka Medical and Pharmaceutical UniversityTakatsukiOsaka569‐8686Japan
| |
Collapse
|
25
|
John T, Ciuleanu TE, Cobo Dols M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Cheng Y, Felip E, Juan Vidal O, Alexandru A, Paz-Ares L, Lu S, Reck M, Hu N, Zhang X, Grootendorst D, Eccles L, Carbone D. 1049P Clinical outcomes in patients (pts) with tumor PD-L1 < 1% with first-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) vs chemo alone for metastatic NSCLC (mNSCLC): Results from CheckMate 9LA. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
26
|
Hu N, Tanaka H, Kakino R, Yoshikawa S, Miyao M, Akita K, Aihara T, Nihei K, Ono K. Improvement in the neutron beam collimation for application in boron neutron capture therapy of the head and neck region. Sci Rep 2022; 12:13778. [PMID: 35962034 PMCID: PMC9374716 DOI: 10.1038/s41598-022-17974-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2022] [Accepted: 08/03/2022] [Indexed: 12/03/2022] Open
Abstract
In June 2020, the Japanese government approved boron neutron capture therapy for the treatment of head and neck cancer. The treatment is usually performed in a single fraction, with the neutron irradiation time being approximately 30–60 min. As neutrons scatter in air and loses its intensity, it is preferable to bring the patient as close to the beam port as possible to shorten the irradiation time. However, this can be a challenge, especially for patients with head and neck cancer, as the shoulders are an obstacle to a clean positioning. In this study, a novel neutron collimation system for an accelerator based neutron source was designed to allow for a more comfortable treatment, without compromising the irradiation time. Experimental measurements confirmed the simulation results and showed the new collimator can reduce the irradiation time by approximately 60% (under the same condition where the distance between the source and the patient surface was kept the same). The dose delivered to the surrounding healthy tissue was reduced with the new collimator, showing a 25% decrease in the D50 of the mucosal membrane. Overall, the use of the newly designed collimator will allow for a more comfortable treatment of the head and neck region, reduce the treatment time, and reduce the dose delivered to the surrounding healthy tissue.
Collapse
Affiliation(s)
- Naonori Hu
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Takatsuki, Japan. .,Institute for Integrated Radiation and Nuclear Science, Kyoto University, Osaka, Japan.
| | - Hiroki Tanaka
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Osaka, Japan
| | - Ryo Kakino
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Takatsuki, Japan
| | - Syuushi Yoshikawa
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Takatsuki, Japan
| | - Mamoru Miyao
- Central Department of Radiology, Osaka Medical and Pharmaceutical University Hospital, Takatsuki, Japan
| | - Kazuhiko Akita
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Takatsuki, Japan
| | - Teruhito Aihara
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Takatsuki, Japan
| | - Keiji Nihei
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.,Department of Radiation Oncology, Osaka Medical and Pharmaceutical University Hospital, Takatsuki, Japan
| | - Koji Ono
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Takatsuki, Japan
| |
Collapse
|
27
|
Hu N, Han M, Zhou B, Guo L, Li ZS. [Hepatoblastoma in elderly female: report of a case]. Zhonghua Bing Li Xue Za Zhi 2022; 51:771-773. [PMID: 35922173 DOI: 10.3760/cma.j.cn112151-20220524-00447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Affiliation(s)
- N Hu
- Department of Pathology, Xijing Hospital, the Air Force Military Medical University, Xi'an 710032, China Department of Pathology, Northwest Woman's and Children's Hospital, Xi'an 710061, China
| | - M Han
- Department of Pathology, Xijing Hospital, the Air Force Military Medical University, Xi'an 710032, China
| | - B Zhou
- Department of General Hepatobiliary Surgery, the Second Affiliated Hospital of Shaanxi University of Chinese Medicine, Xi'an 712046, China
| | - L Guo
- Department of Pathology, Xijing Hospital, the Air Force Military Medical University, Xi'an 710032, China
| | - Z S Li
- Department of Pathology, Xijing Hospital, the Air Force Military Medical University, Xi'an 710032, China
| |
Collapse
|
28
|
Wang MM, Sun X, Hu N, Hou ZQ, Xiong WP, Wang YJ, Fan ZM, Wang HB. [The changes of blood-labyrinth barrier in idiopathic sudden sensorineural hearing loss and the relationship with clinical features and prognosis]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2022; 57:937-942. [PMID: 36058659 DOI: 10.3760/cma.j.cn115330-20210705-00429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Objective: To investigate the clinical features and prognosis in patients with idiopathic sudden sensorineural hearing loss (ISSNHL) with blood-labyrinth barrier breakdown (BLB-B). Methods: Clinical data of patients with unilateral ISSNHL hospitalized from December 2017 to December 2018 were retrospectively analyzed. According to the results of 3D-FLAIR MRI and enhanced MRI scanning, these patients were divided into two groups, i.e., normal and abnormal inner ear groups. The patients in abnormal inner ear group were further divided into two subgroups: BLB-B and BLB-B with exudation. The differences and correlations among the groups in clinical characteristics, in terms of gender, age, deafness side, basic diseases, dizziness/vertigo, vestibular function, hearing loss degree, as well as classification of hearing curve, and prognosis were analyzed by statistical software SPSS 23.0. Results: Data were collected from 150 cases, in which 68 were male and 82 were female, aged (46.2±14.6) years, including 67 cases with normal inner ears and 83 cases with abnormal inner ears (13 cases with BLB-B; 70 cases with BLB-B and exudation). The dizziness/vertigo incidence, side ratio, hearing loss degree, classification of hearing curve, vestibular dysfunction (vestibular double temperature test, HIT and VAT) and therapeutic effect were different between normal and abnormal inner ear groups (P<0.05). The dizziness/vertigo incidence, side ratio, hearing loss degree, classification of hearing curve, vestibular dysfunction (vestibular double temperature test, o/cVEMP, HIT and VAT) and therapeutic effect were different among normal inner ear, BLB-B and BLB-B with exudation groups (P<0.05). Pairwise comparison between groups revealed that vestibular dysfunction (vestibular double temperature test, o/cVEMP, HIT and VAT) and therapeutic effect were different between normal inner ear and BLB-B groups (P<0.05); The dizziness/vertigo incidence, side ratio, hearing loss degree, classification of hearing curve, vestibular dysfunction (vestibular double temperature test, o/cVEMP, HIT and VAT) and therapeutic effect were different between normal inner ear and BLB-B with exudation groups (P<0.05). There was no significant different between BLB-B and BLB-B with exudation groups. Conclusion: BLB-B displayed by 3D-FLAIR MRI manifestation in ISSNHL patients indicates more serious cochlear and vestibular dysfunction, and worse therapeutic effect.
Collapse
Affiliation(s)
- M M Wang
- Department of Otological Medicine, Shandong Provincial ENT Hospital, Shandong University, Jinan 250022, China
| | - X Sun
- Department of Otological Medicine, Shandong Provincial ENT Hospital, Shandong University, Jinan 250022, China
| | - N Hu
- Medical Imaging Center, Shandong Provincial ENT Hospital, Shandong University, Jinan 250022, China
| | - Z Q Hou
- Department of Otological Medicine, Shandong Provincial ENT Hospital, Shandong University, Jinan 250022, China
| | - W P Xiong
- Department of Otological Medicine, Shandong Provincial ENT Hospital, Shandong University, Jinan 250022, China
| | - Y J Wang
- Department of Otological Medicine, Shandong Provincial ENT Hospital, Shandong University, Jinan 250022, China
| | - Z M Fan
- Department of Otology Center, Shandong Provincial ENT Hospital, Shandong University, Jinan 250022, China
| | - H B Wang
- Department of Otology Center, Shandong Provincial ENT Hospital, Shandong University, Jinan 250022, China
| |
Collapse
|
29
|
Higashino M, Aihara T, Ozaki A, Hu N, Isohashi K, Ono K, Nihei K, Kurisu Y, Kawata R. Successful salvage surgery of the residual tumor after boron neutron capture therapy (BNCT): A case report. Appl Radiat Isot 2022; 189:110420. [DOI: 10.1016/j.apradiso.2022.110420] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2021] [Revised: 08/08/2022] [Accepted: 08/12/2022] [Indexed: 11/02/2022]
|
30
|
Zhang Y, Hu N, Hua Y, Richmond KL, Dong F, Ren J. Corrigendum to "Cardiac overexpression of metallothionein rescues cold exposure-induced myocardial contractile dysfunction through attenuation of cardiac fibrosis despite cardiomyocyte mechanical anomalies" [Free Radic. Biol. Med. 53 (2) (2012 Jul 15) 194-207]. Free Radic Biol Med 2022; 188:103-104. [PMID: 35738068 DOI: 10.1016/j.freeradbiomed.2022.06.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Affiliation(s)
- Y Zhang
- Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China; Center for Cardiovascular Research and Alternative Medicine, University of Wyoming College of Health Sciences, Laramie, WY, 82071, USA
| | - N Hu
- Center for Cardiovascular Research and Alternative Medicine, University of Wyoming College of Health Sciences, Laramie, WY, 82071, USA
| | - Y Hua
- Center for Cardiovascular Research and Alternative Medicine, University of Wyoming College of Health Sciences, Laramie, WY, 82071, USA
| | - K L Richmond
- Center for Cardiovascular Research and Alternative Medicine, University of Wyoming College of Health Sciences, Laramie, WY, 82071, USA
| | - F Dong
- Center for Cardiovascular Research and Alternative Medicine, University of Wyoming College of Health Sciences, Laramie, WY, 82071, USA
| | - J Ren
- Center for Cardiovascular Research and Alternative Medicine, University of Wyoming College of Health Sciences, Laramie, WY, 82071, USA.
| |
Collapse
|
31
|
Kakino R, Hu N, Isohashi K, Aihara T, Nihei K, Ono K. Comprehensive evaluation of dosimetric impact against position errors in accelerator-based BNCT under different treatment parameter settings. Med Phys 2022; 49:4944-4954. [PMID: 35758307 PMCID: PMC9541895 DOI: 10.1002/mp.15823] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2022] [Revised: 06/07/2022] [Accepted: 06/07/2022] [Indexed: 11/12/2022] Open
Abstract
Background Patients who undergo accelerator‐based (AB) boron neutron capture therapy (BNCT) for head and neck cancer in the sitting position are generally uncomfortably immobilized, and patient motion during this treatment may be greater than that in other radiotherapy techniques. Furthermore, the treatment time of BNCT is relatively long (up to approximately 1 h), which increases the possibility of patient movement during treatment. As most BNCT irradiations are performed in a single fraction, the dosimetric error due to patient motion is of greater consequence and needs to be evaluated and accounted for. Several treatment parameters are required for BNCT dose calculation. Purpose To investigate the dosimetric impacts (DIs) against position errors using a simple cylindrical phantom for an AB‐BNCT system under different treatment parameter settings. Methods The treatment plans were created in RayStation and the dose calculation was performed using the NeuCure® dose engine. A cylindrical phantom (16 cm diameter × 20 cm height) made of soft tissue was modeled. Dummy tumors in the form of a 3‐cm‐diameter sphere were arranged at depths of 2.5 and 6.5 cm (denoted by T2.5 and T6.5, respectively). Reference plans were created by setting the following parameters: collimator size = 10, 12, or 15 cm in diameter, collimator‐to‐surface distance (CSD) = 4.0 or 8.0 cm, tumor‐to‐blood ratio (T/B ratio) using 18F‐fluoro‐borono‐phenylalanine = 2.5 or 5.0, and 10B concentration in blood = 20, 25, or 30 ppm. The prescribed dose was D95% ≥ 20 Gy‐eq for both T2.5 and T6.5. Based on the reference plans, phantom‐shifted plans were created in 26 directions [all combinations of left–right (LR), anterior–posterior (AP), and superior–inferior (SI) directions) and three distances (1.0, 2.0, and 3.0 cm). The DIs were evaluated at D80% of the tumors. The shift direction dependency of the DI in the LR, AP, and SI directions was evaluated by conducting a multiple regression analysis (MRA) and other analyses where required. Results The coefficients of the MRA of the DIs for LR, AP, and SI shifts were −0.08, 2.16, and −0.04 (p‐values = 0.084, <0.01, and 0.334) for T2.5 and −0.05, 2.08, and 0.15 (p‐values = 0.526, <0.01, and 0.065) for T6.5, respectively. The analysis of variance showed that DIs due to the AP shift were significantly greater for smaller collimator sizes on T2.5 and smaller CSD on T6.5. Dose reduction due to SI or LR (lateral) shifts was significantly greater for smaller collimator sizes on both T2.5 and T6.5 and smaller CSD on T2.5, according to the Student's t‐test. There were no significant differences in the DIs against both the AP shift and the lateral shift between the different T/B ratios and 10B concentrations. Conclusion The DIs were largely affected by the shift in the AP direction and were influenced by the different treatment parameters.
Collapse
Affiliation(s)
- Ryo Kakino
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki-shi, Osaka, 569-8686, Japan
| | - Naonori Hu
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki-shi, Osaka, 569-8686, Japan.,Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2 Asashiro-nishi Kumatori-cho, Osaka, 590-0494, Japan
| | - Kayako Isohashi
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki-shi, Osaka, 569-8686, Japan
| | - Teruhito Aihara
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki-shi, Osaka, 569-8686, Japan
| | - Keiji Nihei
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki-shi, Osaka, 569-8686, Japan.,Department of Radiation Oncology, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki-shi, Osaka, 569-8686, Japan
| | - Koji Ono
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki-shi, Osaka, 569-8686, Japan
| |
Collapse
|
32
|
Jian HR, Hu N, Li XF, Lyu YF, Li YW, Fan ZM, Wang HB, Zhang DG. [Correlation analysis of 3D-FLAIR MRI characteristics of the inner ear and vestibular function in the patients with vestibular neuritis]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2022; 57:578-583. [PMID: 35610676 DOI: 10.3760/cma.j.cn115330-20210203-00056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Objective: The characteristics of 3D-FLAIR MRI images of the inner ear of patients with vestibular neuritis were preliminarily studied to explore the possible pathogenesis of vestibular neuritis, and the correlation analysis was conducted in combination with vestibular function to provide a basis for accurate diagnosis of vestibular neuritis. Methods: A total of 36 patients with vestibular neuritis (VN) from December 2019 to October 2020 were collected from the Vertigo Department of Shandong Provincial ENT Hospital, Cheeloo College of Medicine, Shandong University. There were 36 cases (18 females, 18 males) with unilateral acute vestibular neuritis, 17 cases of left ear and 19 cases of right ear. According to the results of 3D-FLAIR MRI in the inner ears, the patients were divided into the enhanced group and the non-enhanced group (the health side served as the normal control group). The results of vestibular function examination in the two groups were compared. SPSS19.0 software was used for statistical processing to analyze the relationship between the vestibular function and the characteristics of 3D-FLAIR imaging in the inner ears. Results: Abnormal enhancement of 3D-FLAIR was found in 31 cases (86.1%) of the 36 cases, including 14 cases of both vestibular nerve and vestibular terminal organ enhancement, eight cases of superior vestibular nerve enhancement alone, seven cases of vestibular terminal organ enhancement alone, and two cases of cochlear enhancement alone. Observation of abnormal reinforcement of vestibular nerve showed: twenty-one cases of superior vestibular nerve reinforcement, one case of superior and inferior vestibular nerve reinforcement. No abnormalities were found in 3D-FLAIR of inner ear in 5 cases. According to the analysis of vestibular function results, there were 19 cases (52.8%) with total vestibular involvement, sixteen cases (44.4%) with superior vestibular involvement alone, and one case (2.8%) with inferior vestibular involvement alone. Comparison of vestibular function between the five cases (non-enhancement group) and the 31 cases (enhanced group) in the 3D-FLAIR group of the inner ears showed that the CP values of caloric tests in the enhanced group were higher (60.81±3.49 vs 34.12±7.37), with statistically significant difference (t=-2.898, P<0.01). Conclusion: In patients with vestibular neuritis, 3D-FLAIR MRI scan of the inner ear provides visual imaging evidence for clinical practice, considering that the lesion site of vestibular neuritis is not only in the vestibular nerve, but also in the vestibular end organ. Patients with 3D-FLAIR enhanced in the inner ear may have more significant vestibular function damage.
Collapse
Affiliation(s)
- H R Jian
- Department of Vertigo Disease, Shandong Provincial ENT Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250022, China Shandong Institute of Otolaryngology, Jinan 250022, China
| | - N Hu
- Medical Imaging Center, Shandong Provincial ENT Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250022, China
| | - X F Li
- Department of Vertigo Disease, Shandong Provincial ENT Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250022, China Shandong Institute of Otolaryngology, Jinan 250022, China
| | - Y F Lyu
- Department of Vertigo Disease, Shandong Provincial ENT Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250022, China Shandong Institute of Otolaryngology, Jinan 250022, China
| | - Y W Li
- Department of Vertigo Disease, Shandong Provincial ENT Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250022, China Shandong Institute of Otolaryngology, Jinan 250022, China
| | - Z M Fan
- Department of Vertigo Disease, Shandong Provincial ENT Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250022, China Shandong Institute of Otolaryngology, Jinan 250022, China
| | - H B Wang
- Department of Vertigo Disease, Shandong Provincial ENT Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250022, China Shandong Institute of Otolaryngology, Jinan 250022, China
| | - D G Zhang
- Department of Vertigo Disease, Shandong Provincial ENT Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250022, China Shandong Institute of Otolaryngology, Jinan 250022, China
| |
Collapse
|
33
|
Montesino B, Hu N, Lozano J, Sackstein R, Chandler K. Association Between Glycosyltransferase Expression and Survival in Head and Neck Cancer. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2021.12.069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
34
|
Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, Kaplan M, Talbot T, Monnet I, Hiret S, Baas P, Nowak A, Fujimoto N, Tsao A, Mansfield A, Popat S, Zhang X, Hu N, Balli D, Spires T, Zalcman G. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol 2022; 33:488-499. [DOI: 10.1016/j.annonc.2022.01.074] [Citation(s) in RCA: 16] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Accepted: 01/24/2022] [Indexed: 12/11/2022] Open
|
35
|
Liao JY, Wang ZY, Liu JC, Hu N, Liang X, Huang W. [Comparison of hip offset and rotation center reconstruction between robot-assisted and manual total hip arthroplasty]. Zhonghua Yi Xue Za Zhi 2022; 102:36-42. [PMID: 34991235 DOI: 10.3760/cma.j.cn112137-20210804-01737] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Objective: To compare the differences of hip offset and rotation center reconstruction between robot-assisted and manual total hip arthroplasty (THA). Methods: Patients underwent robot-assisted and manual THA from May to September of 2020 in the First Affiliated Hospital of Chongqing Medical University were enrolled in this study. The patients included 27 patients (28 hips) in robot-assisted THA (rTHA) group and 29 patients (31 hips) in manual THA (mTHA) group. In rTHA group, there were 16 males and 11 females, with a mean age of (59±13) years. In mTHA group, there were 18 males and 11 females, with a mean age of (63±14) years. Basic information, including gender, age, body mass index (BMI), diagnosis and functional scoring etc, were recorded. In rTHA group, Mako robot system was used for preoperative planning, intraoperative real-time location and navigation. In mTHA group, traditional preoperative template design and surgical procedure were carried out. Operation time and functional scoring were compared postoperatively. Femoral offset, acetabular offset, global offset, rotation center changes in vertical and horizontal directions were measured on pelvis X-ray and analyzed. The correlation between intraoperative feedback of global offset change in robot system and postoperative measured global offset were analyzed. Results: Operation time in rTHA group was (80±10) min, which was statistically longer than that in mTHA group ((58±18) min, P<0.001). With 6 months' follow-up, the Harris scoring in rTHA group was 94.9±2.8, which was statistically higher than that in mTHA group (93.1±2.8, P=0.017), however there was no statistic difference in WOMAC scoring between rTHA and mTHA group (7.0±3.8 vs 7.1±2.4, P=0.840). Absolute global offset change within 5 mm, 5-10 mm and lager than 10 mm were 71.4%(20/28), 28.6%(8/28) and 0 in rTHA group, which were 45.2%(14/31), 29.0%(9/31) and 25.8%(8/31) in mTHA group (all P<0.05). A positive relation was found between intraoperative feedback of global offset change in robot system and postoperative measured global offset in rTHA group (r=0.77, P<0.001). It was found that rotation center changes concentrated in outer upper quadrant in both groups, and rotation center change in rTHA group concentrated mainly in the area less than 10 mm, however, rotation center change in mTHA group was more dispersive compared with rTHA group. Conclusion: rTHA may accurately reconstruct hip offset and rotation center, intraoperation feedback of global offset change may be an effective reference.
Collapse
Affiliation(s)
- J Y Liao
- Department of Orthopedics, the First Affiliated Hospital of Chongqing Medical University, Orthopedic Laboratory of Chongqing Medical University, Chongqing 400016, China
| | - Z Y Wang
- Department of Orthopedics, the First Affiliated Hospital of Chongqing Medical University, Orthopedic Laboratory of Chongqing Medical University, Chongqing 400016, China
| | - J C Liu
- Department of Orthopedics, the First Affiliated Hospital of Chongqing Medical University, Orthopedic Laboratory of Chongqing Medical University, Chongqing 400016, China
| | - N Hu
- Department of Orthopedics, the First Affiliated Hospital of Chongqing Medical University, Orthopedic Laboratory of Chongqing Medical University, Chongqing 400016, China
| | - X Liang
- Department of Orthopedics, the First Affiliated Hospital of Chongqing Medical University, Orthopedic Laboratory of Chongqing Medical University, Chongqing 400016, China
| | - W Huang
- Department of Orthopedics, the First Affiliated Hospital of Chongqing Medical University, Orthopedic Laboratory of Chongqing Medical University, Chongqing 400016, China
| |
Collapse
|
36
|
Teng E, Manser PT, Shah M, Pickthorn K, Hu N, Djakovic S, Swendsen H, Blendstrup M, Faccin G, Ostrowitzki S, Sink KM. The Use of Episodic Memory Tests for Screening in Clinical Trials for Early Alzheimer's Disease: A Comparison of the Free and Cued Selective Reminding Test (FCSRT) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). J Prev Alzheimers Dis 2022; 10:41-49. [PMID: 36641609 DOI: 10.14283/jpad.2022.101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND Screening procedures for early Alzheimer's disease (AD) trials seek to efficiently identify participants who fulfill clinical and biomarker criteria for AD and enrich for those most likely to experience significant clinical progression during the study. Episodic memory performance is often assessed in screening, but the utility of different memory tests for optimizing screening efficiency and/or rates of clinical progression remains uncertain. OBJECTIVES Cross-study comparisons of the effects of inclusion criteria based on performance on the Free and Cued Selective Reminding Test (FCSRT) or the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) on screen-failure rates for episodic memory and β-amyloid (Aβ) positivity (by CSF or PET) and on subsequent rates of clinical disease progression in randomized participants across three clinical trials in early (prodromal-to-mild) AD. DESIGN Secondary analyses of cross-sectional and longitudinal clinical trial data. SETTING Multi-center international clinical trials. PARTICIPANTS Individuals with prodromal-to-mild AD screened and/or randomized in clinical trials for crenezumab (CREAD, CREAD2) or semorinemab (Tauriel). Cross-sectional analyses of screening data for episodic memory impairment included participants from CREAD2 (n=2897) and Tauriel (n=887) and for Aβ positivity included participants from CREAD (n=1138), CREAD2 (n=1119), and Tauriel (n=483). Longitudinal analyses of rates of clinical progression included participants from CREAD (n=779), CREAD2 (n=773), and Tauriel (n=331). MEASUREMENTS Cross-sectional analyses examined eligibility rates per cutoffs defined for the FCSRT (CREAD, CREAD2) or RBANS (Tauriel) and per Aβ positivity using CSF and/or PET biomarkers. Longitudinal analyses examined rates of clinical progression on the Clinical Dementia Rating-Sum of Boxes (CDR-SB), the 13-item version of the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog13), and Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale (ADCS-ADL). RESULTS Lower rates of study eligibility per episodic memory criteria were seen with the FCSRT (CREAD2) relative to the RBANS (Tauriel), but similar rates of eligibility per Aβ positivity criteria were seen amongst participants with episodic memory impairment per the cutoffs used on either assessment. Similar rates of clinical decline over 18 months on the CDR-SB, ADAS-Cog13, and ADCS-ADL were observed in study populations enriched using the FCSRT (CREAD, CREAD2) or the RBANS (Tauriel). CONCLUSIONS Cutoffs for episodic memory impairment on the FCSRT used in the CREAD and CREAD2 studies are more stringent than those on the RBANS used in the Tauriel study, resulting in lower rates of eligibility. However, given that study enrichment with either test yields similar rates of Aβ positivity and clinical progression, considerations beyond these factors may drive the decision of which assessment to use for screening in early AD clinical trials.
Collapse
Affiliation(s)
- E Teng
- Edmond Teng, MD, PhD, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, Tel: 650-467-1661, Fax: 650-467-2887,
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Yamamoto S, Yabe T, Hu N, Kanai Y, Tanaka H, Ono K. Optical imaging of lithium-containing zinc sulfate plate in water during irradiation of neutrons from boron neutron capture therapy (BNCT) system. Med Phys 2021; 49:1822-1830. [PMID: 34958515 DOI: 10.1002/mp.15424] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2021] [Revised: 11/29/2021] [Accepted: 12/06/2021] [Indexed: 11/10/2022] Open
Abstract
PURPOSE Optical imaging of ionizing radiation is a possible method for dose distribution measurements. However, it is not clear whether the imaging method is also applicable to neutrons. To clarify this, we performed the imaging of neutrons in water from boron neutron capture therapy (BNCT) systems. Such systems require efficient distribution measurements of neutrons for quality assessment (QA) of the beams. METHOD A water-filled phantom was irradiated from the side with an epithermal neutron beam, in which a lithium-containing zinc sulfate (Li-ZnS(Ag)) plate was set in the beam direction, and during this irradiation the scintillation of the plate was imaged using a cooled CCD camera. In the imaging, Li-6 in the Li-ZnS(Ag) plate captures neutrons and converts them to alpha particles (He-4) and tritium (H-3), while ZnS(Ag) in the Li-ZnS(Ag) plate produces scintillation light in the plate. We also conducted Monte Carlo simulation and compared its results with the experimental results. RESULTS The image of the emitted light from the Li-ZnS(Ag) plate was clearly obtained with an imaging time of 0.5 s. The depth and lateral profiles of the measured image using the Li-ZnS(Ag) plate showed the same shapes as the neutron distributions measured with gold foil, within a difference of 8%. The destructive effect of neutrons on the CCD camera increased ∼3 times, but the unit was still working after the measurement. CONCLUSION The optical imaging of neutrons in water is possible, and it has the potential to be a new method for efficient QA as well as for research on neutrons. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Seiichi Yamamoto
- Department of Integrated Health Science, Nagoya University Graduate School of Medicine
| | - Takuya Yabe
- Department of Integrated Health Science, Nagoya University Graduate School of Medicine.,Department of Radiation Technology, Nagoya University Hospital
| | - Naonori Hu
- Kansai BNCT Medical Center, Osaka Medical College
| | - Yasukazu Kanai
- Kansai BNCT Medical Center, Osaka Medical College.,Department of Biofunctional Analysis, Osaka University of Pharmaceutical Science
| | - Hiroki Tanaka
- Institute for Integrated Radiation and Nuclear Science, Kyoto University
| | - Koji Ono
- Kansai BNCT Medical Center, Osaka Medical College
| |
Collapse
|
38
|
Hu N, Tanaka H, Kakino R, Yoshikawa S, Miyao M, Akita K, Isohashi K, Aihara T, Nihei K, Ono K. Evaluation of a treatment planning system developed for clinical boron neutron capture therapy and validation against an independent Monte Carlo dose calculation system. Radiat Oncol 2021; 16:243. [PMID: 34952608 PMCID: PMC8709965 DOI: 10.1186/s13014-021-01968-2] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2021] [Accepted: 12/15/2021] [Indexed: 11/16/2022] Open
Abstract
Boron neutron capture therapy (BNCT) for the treatment of unresectable, locally advanced, and recurrent carcinoma of the head and neck cancer has been approved by the Japanese government for reimbursement under the national health insurance as of June 2020. A new treatment planning system for clinical BNCT has been developed by Sumitomo Heavy Industries, Ltd. (Sumitomo), NeuCure® Dose Engine. To safely implement this system for clinical use, the simulated neutron flux and gamma ray dose rate inside a water phantom was compared against experimental measurements. Furthermore, to validate and verify the new planning system, the dose distribution inside an anthropomorphic head phantom was compared against a BNCT treatment planning system SERA and an in-house developed Monte Carlo dose calculation program. The simulated results closely matched the experimental results, within 5% for the thermal neutron flux and 10% for the gamma ray dose rate. The dose distribution inside the head phantom closely matched with SERA and the in-house developed dose calculation program, within 3% for the tumour and a difference of 0.3 Gyw for the brain.
Collapse
Affiliation(s)
- Naonori Hu
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Osaka-fu Takatsuki-shi Daigakumachi 2-7, Takatsuki, Japan. .,Institute for Integrated Radiation and Nuclear Science, Kyoto University, Kyoto, Japan.
| | - Hiroki Tanaka
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Kyoto, Japan
| | - Ryo Kakino
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Osaka-fu Takatsuki-shi Daigakumachi 2-7, Takatsuki, Japan
| | - Syuushi Yoshikawa
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Osaka-fu Takatsuki-shi Daigakumachi 2-7, Takatsuki, Japan
| | - Mamoru Miyao
- Central Department of Radiology, Osaka Medical and Pharmaceutical University Hospital, Takatsuki, Japan
| | - Kazuhiko Akita
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Osaka-fu Takatsuki-shi Daigakumachi 2-7, Takatsuki, Japan
| | - Kayako Isohashi
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Osaka-fu Takatsuki-shi Daigakumachi 2-7, Takatsuki, Japan
| | - Teruhito Aihara
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Osaka-fu Takatsuki-shi Daigakumachi 2-7, Takatsuki, Japan
| | - Keiji Nihei
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Osaka-fu Takatsuki-shi Daigakumachi 2-7, Takatsuki, Japan.,Department of Radiation Oncology, Osaka Medical and Pharmaceutical University Hospital, Takatsuki, Japan
| | - Koji Ono
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Osaka-fu Takatsuki-shi Daigakumachi 2-7, Takatsuki, Japan
| |
Collapse
|
39
|
Sasaki A, Tanaka H, Takata T, Tamari Y, Watanabe T, Hu N, Kawabata S, Kudo Y, Mitsumoto T, Sakurai Y, Suzuki M. Development of an irradiation method for superficial tumours using a hydrogel bolus in an accelerator-based BNCT. Biomed Phys Eng Express 2021; 8. [PMID: 34823226 DOI: 10.1088/2057-1976/ac3d73] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2021] [Accepted: 11/25/2021] [Indexed: 11/11/2022]
Abstract
The aim of this study is the development of an irradiation method for the treatment of superficial tumours using a hydrogel bolus to produce thermal neutrons in accelerator-based Boron Neutron Capture Therapy (BNCT).To evaluate the neutron moderating ability of a hydrogel bolus, a water phantom with a hydrogel bolus was irradiated with an epithermal neutron beam from a cyclotron-based epithermal neutron source. Phantom simulating irradiation to the plantar position was manufactured using three-dimensional printing technology to perform an irradiation test of a hydrogel bolus. Thermal neutron fluxes on the surface of a phantom were evaluated and the results were compared with the Monte Carlo-based Simulation Environment for Radiotherapy Applications (SERA) treatment planning software. It was confirmed that a hydrogel bolus had the same neutron moderating ability as water, and the calculation results from SERA aligned with the measured values within approximately 5%. Furthermore, it was confirmed that the thermal neutron flux decreased at the edge of the irradiation field. It was possible to uniformly irradiate thermal neutrons by increasing the bolus thickness at the edge of the irradiation field, thereby successfully determining uniform dose distribution. An irradiation method for superficial tumours using a hydrogel bolus in the accelerator-based BNCT was established.
Collapse
Affiliation(s)
- Akinori Sasaki
- Graduate School of Engineering, Kyoto University, Kyoutodaigaku-Katsura, Kyoto, Japan
| | - Hiroki Tanaka
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Kumatori-cho, Osaka, Japan
| | - Takushi Takata
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Kumatori-cho, Osaka, Japan
| | - Yuki Tamari
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Kumatori-cho, Osaka, Japan
| | - Tsubasa Watanabe
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Kumatori-cho, Osaka, Japan
| | - Naonori Hu
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Takatsuki, Japan
| | - Shinji Kawabata
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki, Japan
| | | | | | - Yoshinori Sakurai
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Kumatori-cho, Osaka, Japan
| | - Minoru Suzuki
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Kumatori-cho, Osaka, Japan
| |
Collapse
|
40
|
Yoshimura K, Kashiwagi H, Kawabata S, Fukuo Y, Takeuchi K, Hiramatsu R, Hu N, Tanaka H, Suzuki M, Miyatake SI, Wanibuchi M. TB-6 Experimental evaluation of the therapeutic potential of boron neutron capture therapy in primary central nervous system lymphoma. Neurooncol Adv 2021. [PMCID: PMC8648232 DOI: 10.1093/noajnl/vdab159.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022] Open
Abstract
Background: High-dose methotrexate and whole brain radiation therapy (WBRT) is the recommended treatment for primary central nervous system lymphoma (PCNSL). Although the initial treatment is successful, the recurrence rate is high and the prognosis is poor. Boron neutron capture therapy (BNCT) is a nuclear reaction-based tumor cell-selective particle irradiation that occurs when non-radioactive boron-10 is irradiated with neutrons to produce α particles (10B [n, α] 7Li). In this study, we conducted a basic research to explore the possibility of BNCT as a treatment option for PCNSL. Methods: Cellular uptake of boron using human lymphoma cell-lines after exposure to boronophenylalanine (BPA) were evaluated. The cytotoxicity of lymphoma cells by photon irradiation or neutron irradiation with BPA were also evaluated. The lymphoma cells were implanted into the mouse brain and the bio-distribution of boron after administration of BPA were measured. In neutron irradiation studies, the therapeutic effect of BNCT on mouse CNSL models were evaluated in terms of survival time. Results: The boron concentration in lymphoma cells after BPA exposure was sufficiently high, and lymphoma cells showed cytotoxicity by photon irradiation, and also by BNCT. In in vivo bio-distribution study, lymphoma cells showed enough uptake of BPA with well contrasted to the brain. In the neutron irradiation experiment, the BNCT group showed a significant prolongation in their survival time compared to the control group. Conclusions: In our study, BNCT showed its effectiveness for PCNSL in a mouse brain tumor model. PCNSL is a radio-sensitive tumor with a extremely good response rate, but it also has a high recurrence rate / a high rate of adverse events, so there is no effective treatment for recurrence after treatment. Our translational study showed that BNCT is possibly have an important role against PCNSL during the therapy lines as a new treatment option for PCNSL patients.
Collapse
Affiliation(s)
| | | | | | - Yusuke Fukuo
- Osaka Medical and Pharmaceutical University, Osaka, Japan
| | - Koji Takeuchi
- Osaka Medical and Pharmaceutical University, Osaka, Japan
| | - Ryo Hiramatsu
- Osaka Medical and Pharmaceutical University, Osaka, Japan
| | | | - Hiroki Tanaka
- Institute for Integrated Radiation and Nuclear Science, Kyoto University
| | - Minoru Suzuki
- Institute for Integrated Radiation and Nuclear Science, Kyoto University
| | | | | |
Collapse
|
41
|
Yoshimura K, Kawabata S, Kashiwagi H, Fukuo Y, Takeuchi K, Futamura G, Hiramatsu R, Takata T, Tanaka H, Watanabe T, Suzuki M, Hu N, Miyatake SI, Wanibuchi M. Efficacy of Boron Neutron Capture Therapy in Primary Central Nervous System Lymphoma: In Vitro and In Vivo Evaluation. Cells 2021; 10:cells10123398. [PMID: 34943904 PMCID: PMC8699713 DOI: 10.3390/cells10123398] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2021] [Revised: 11/27/2021] [Accepted: 11/29/2021] [Indexed: 11/21/2022] Open
Abstract
Background: Boron neutron capture therapy (BNCT) is a nuclear reaction-based tumor cell-selective particle irradiation method. High-dose methotrexate and whole-brain radiation therapy (WBRT) are the recommended treatments for primary central nervous system lymphoma (PCNSL). This tumor responds well to initial treatment but relapses even after successful treatment, and the prognosis is poor as there is no safe and effective treatment for relapse. In this study, we aimed to conduct basic research to explore the possibility of using BNCT as a treatment for PCNSL. Methods: The boron concentration in human lymphoma cells was measured. Subsequently, neutron irradiation experiments on lymphoma cells were conducted. A mouse central nervous system (CNS) lymphoma model was created to evaluate the biodistribution of boron after the administration of borono-phenylalanine as a capture agent. In the neutron irradiation study of a mouse PCNSL model, the therapeutic effect of BNCT on PCNSL was evaluated in terms of survival. Results: The boron uptake capability of human lymphoma cells was sufficiently high both in vitro and in vivo. In the neutron irradiation study, the BNCT group showed a higher cell killing effect and prolonged survival compared with the control group. Conclusions: A new therapeutic approach for PCNSL is urgently required, and BNCT may be a promising treatment for PCNSL. The results of this study, including those of neutron irradiation, suggest success in the conduct of future clinical trials to explore the possibility of BNCT as a new treatment option for PCNSL.
Collapse
Affiliation(s)
- Kohei Yoshimura
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki 569-8686, Japan; (K.Y.); (H.K.); (Y.F.); (K.T.); (G.F.); (R.H.); (M.W.)
| | - Shinji Kawabata
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki 569-8686, Japan; (K.Y.); (H.K.); (Y.F.); (K.T.); (G.F.); (R.H.); (M.W.)
- Correspondence: ; Tel.: +81-72-63-1221
| | - Hideki Kashiwagi
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki 569-8686, Japan; (K.Y.); (H.K.); (Y.F.); (K.T.); (G.F.); (R.H.); (M.W.)
| | - Yusuke Fukuo
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki 569-8686, Japan; (K.Y.); (H.K.); (Y.F.); (K.T.); (G.F.); (R.H.); (M.W.)
| | - Koji Takeuchi
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki 569-8686, Japan; (K.Y.); (H.K.); (Y.F.); (K.T.); (G.F.); (R.H.); (M.W.)
| | - Gen Futamura
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki 569-8686, Japan; (K.Y.); (H.K.); (Y.F.); (K.T.); (G.F.); (R.H.); (M.W.)
| | - Ryo Hiramatsu
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki 569-8686, Japan; (K.Y.); (H.K.); (Y.F.); (K.T.); (G.F.); (R.H.); (M.W.)
| | - Takushi Takata
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2 Asashiro-Nishi, Kumatori-cho, Sennan 590-0494, Japan; (T.T.); (H.T.); (T.W.); (M.S.)
| | - Hiroki Tanaka
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2 Asashiro-Nishi, Kumatori-cho, Sennan 590-0494, Japan; (T.T.); (H.T.); (T.W.); (M.S.)
| | - Tsubasa Watanabe
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2 Asashiro-Nishi, Kumatori-cho, Sennan 590-0494, Japan; (T.T.); (H.T.); (T.W.); (M.S.)
| | - Minoru Suzuki
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2 Asashiro-Nishi, Kumatori-cho, Sennan 590-0494, Japan; (T.T.); (H.T.); (T.W.); (M.S.)
| | - Naonori Hu
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki 569-8686, Japan; (N.H.); (S.-I.M.)
| | - Shin-Ichi Miyatake
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki 569-8686, Japan; (N.H.); (S.-I.M.)
| | - Masahiko Wanibuchi
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki 569-8686, Japan; (K.Y.); (H.K.); (Y.F.); (K.T.); (G.F.); (R.H.); (M.W.)
| |
Collapse
|
42
|
Reck M, Ciuleanu T, Pluzanski A, Lee J, Bernabe Caro R, Linardou H, Burgers J, Gallardo C, Nishio M, Peters S, Paz-Ares L, Hellmann M, Borghaei H, Ramalingam S, O’Byrne K, Hu N, Bushong J, Eccles L, Grootendorst D, Brahmer J. 122MO Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.10.141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
43
|
Hu N, Wang C, Liao Y, Dai Q, Cao S. Smoking and incidence of insomnia: a systematic review and meta-analysis of cohort studies. Public Health 2021; 198:324-331. [PMID: 34507139 DOI: 10.1016/j.puhe.2021.07.012] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2020] [Revised: 05/28/2021] [Accepted: 07/09/2021] [Indexed: 11/28/2022]
Abstract
OBJECTIVE This study investigated the impact of smoking on the incidence of insomnia. STUDY DESIGN Systematic review and meta-analysis of cohort studies. METHODS PubMed, EMBASE, Web of Science, Cochrane Library, and OVID were searched through March 2020. Cohort studies reporting the effect of smoking on the incidence of insomnia were included. We quantitatively analyzed the basic framework and study characteristics and then pooled estimate effects with 95% confidence intervals (CIs) of outcomes of each included study using fixed-effects meta-analyses. RESULTS This systematic review included six cohort studies involving 12,445 participants. Quantitatively summarized results suggested that smoking could significantly increase the incidence of insomnia (odds ratio [OR]: 1.07, 95% CI: 1.02, 1.13). Regular smoking was significantly associated with the incidence of insomnia (OR = 1.07, 95% CI: 1.01, 1.13). As for occasional smokers and ex-smokers, the pooled analysis did not indicate a significant association (occasional smoker: OR = 2.09, 95% CI: 0.44, 9.95; ex-smoker; OR = 1.02, 95% CI: 0.67, 1.54). Subgroup analysis by age, gender ratio, and region showed a statistically significant relationship between smoking and the incidence of insomnia in specific groups. CONCLUSIONS Integrated longitudinal observational evidence identified smoking as a significant risk factor of insomnia. Considering the limited amount of available studies, more high-quality and prospective cohort studies of large sample sizes are needed to explore details of this association.
Collapse
Affiliation(s)
- N Hu
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China
| | - C Wang
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China
| | - Y Liao
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China
| | - Q Dai
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China
| | - S Cao
- School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
| |
Collapse
|
44
|
Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, Kaplan M, Talbot T, Monnet I, Hiret S, Baas P, Nowak A, Fujimoto N, Tsao A, Mansfield A, Popat S, Zhang X, Hu N, Balli D, Sanzari J, Zalcman G. LBA65 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.2146] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
45
|
Kakino R, Nakamura M, Hu N, Iramina H, Tanaka H, Sakurai Y, Mizowaki T. Photoneutron-induced damage reduction for cardiac implantable electronic devices using neutron-shielding sheets in high-energy X-ray radiotherapy: A phantom study. Phys Med 2021; 89:151-159. [PMID: 34371340 DOI: 10.1016/j.ejmp.2021.07.036] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/05/2021] [Revised: 07/06/2021] [Accepted: 07/28/2021] [Indexed: 12/24/2022] Open
Abstract
PURPOSE To evaluate damage reduction in cardiac implantable electronic devices (CIEDs) caused by photoneutrons in high-energy X-ray radiotherapy using a neutron-shielding sheet (NSS). METHODS The NSS consists of a bolus with a thickness of 1 or 2 cm (Bls1 or Bls2) as a moderator and several absorbers (20%, 50%, or 80% B4C silicone sheet [B4C20, B4C50, or B4C80] or a 40% LiF silicone sheet [LiF40]). First, a linear accelerator (LINAC) with a water-equivalent phantom was modeled in the simulation and measured experimentally. Several NSSs were placed on the phantom, a Eu:LiCaAlF6 scintillator was placed between the phantom and the NSS, and X-rays were irradiated. The relative counts (Cr = counts when placing the NSS or Bls2) were compared between the experiment and simulation. Second, CIED damage was evaluated in the simulation. The relative damage (Dr = damage when placing or not placing the NSS) was compared among all the NSSs. In addition, the γ-ray and leaking X-ray dose from B4C was measured using a dosimetric film. After determining the optimal NSS combination, Dr value analysis was performed by changing the length of one side and the thickness. RESULTS The Cr values of the simulation and experiment agreed within a 30% percentage difference, except for Bare or LiF40-only. The Dr value was reduced by 43% when Bls2 + B4C80 was applied. The photon dose was less than 5 cGy/1500 MU. The Dr values were smaller for the smaller lengths of one side of B4C80 and decreased as the M-layer thickness increased. CONCLUSIONS The CIED damage induced by photoneutrons generated by a LINAC was effectively reduced by applying the optimal NSS.
Collapse
Affiliation(s)
- Ryo Kakino
- Division of Medical Physics, Department of Information Technology and Medical Engineering, Human Health Sciences, Graduate School of Medicine, Kyoto University, 53 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan; Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan; Japan Society for the Promotion of Science, 5-3-1 Kojimachi, Chiyoda-ku, Tokyo 102-0083, Japan
| | - Mitsuhiro Nakamura
- Division of Medical Physics, Department of Information Technology and Medical Engineering, Human Health Sciences, Graduate School of Medicine, Kyoto University, 53 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan; Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan.
| | - Naonori Hu
- Kansai BNCT Medical Center, Osaka Medical College, 2-7 Daigaku-Machi, Takatsuki, Osaka 569-8686, Japan; Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2 Asashiro-nishi Kumatori-cho, Osaka 590-0494, Japan
| | - Hiraku Iramina
- Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - Hiroki Tanaka
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2 Asashiro-nishi Kumatori-cho, Osaka 590-0494, Japan
| | - Yoshinori Sakurai
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2 Asashiro-nishi Kumatori-cho, Osaka 590-0494, Japan
| | - Takashi Mizowaki
- Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| |
Collapse
|
46
|
Tang T, Zhang M, Wendong L, Hu N, Du X, Ran F. Oral Anticoagulant and Antiplatelet Therapy for Peripheral Arterial Disease: A Meta-Analysis of Randomized Controlled Trials. J Vasc Surg 2021. [DOI: 10.1016/j.jvs.2021.04.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
47
|
Zhu J, Hu N, Hou J, Liang X, Wang Y, Zhang H, Wang P, Chen T, Chen W, Wang L. T 1rho mapping of cartilage and menisci in patients with hyperuricaemia at 3 T: a preliminary study. Clin Radiol 2021; 76:710.e1-710.e8. [PMID: 34016388 DOI: 10.1016/j.crad.2021.04.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2021] [Revised: 04/14/2021] [Accepted: 04/27/2021] [Indexed: 11/16/2022]
Abstract
AIM To compare and assess T1rho values of the femorotibial cartilage compartments and subregional menisci in patients with hyperuricaemia at 3 T. MATERIALS AND METHODS Thirty-two patients were enrolled in the study and were subdivided into two subgroups: 15 healthy controls (three women, 12 men; mean age = 45.3 ± 10.9 years, age range 25-72 years) and 17 patients with asymptomatic hyperuricaemia (two women, 15 men; mean age = 44.4 ± 12.7 years, age range 26-77 years). All patients were evaluated using 3 T magnetic resonance imaging (MRI) using an eight-channel phased-array knee coil (transmit-receive). Wilcoxon's rank sum test and analysis of covariance (ANCOVA) were conducted to determine whether there were any statistically significant differences in the T1rho values of the femorotibial cartilage compartments and subregional menisci between the two subgroups. RESULTS Lateral tibial cartilage (45.8 ± 2.9 ms) in the healthy subgroup had significantly lower (p<0.05) T1rho values than those of all subcompartments of the femorotibial cartilage in the hyperuricaemia subgroup. The lateral femoral cartilage (LF) in hyperuricaemia (54.6 ± 3.9 ms) subgroup had significantly higher (p<0.05) T1rho values than those of all subcompartments of the femorotibial cartilage except the LF in the healthy subgroup. Significantly higher (p<0.05) T1rho values existed in the LF of the healthy (54.6 ± 4.7 ms) subgroup in comparison with those of all subcompartments of femorotibial cartilage except the LF in hyperuricaemia subgroup. CONCLUSIONS T1rho values in certain compartments of the femorotibial cartilage in patients with hyperuricaemia are elevated compared to those in healthy patients presumably due to reduced proteoglycan content, to which particular attention should be paid when diagnosing and treating the patients with hyperuricaemia in a clinical setting.
Collapse
Affiliation(s)
- J Zhu
- Department of Radiology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215004, China
| | - N Hu
- Department of Radiology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215004, China
| | - J Hou
- Department of Imaging and Interventional Radiology, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, NT, Hong Kong Special Administrative Region, China
| | - X Liang
- Mary Mackillop Institute for Health Research, Australian Catholic University, Melbourne, Australia; Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia
| | - Y Wang
- Department of Radiation Physics, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310022, China
| | - H Zhang
- Department of Imaging and Interventional Radiology, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, NT, Hong Kong Special Administrative Region, China
| | - P Wang
- Vanderbilt University Institute of Imaging Science, 1161 21st Avenue South, MCN AA-1105, Nashville, TN, 37232-2310, USA
| | - T Chen
- Department of Radiology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215004, China
| | - W Chen
- Department of Imaging and Interventional Radiology, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, NT, Hong Kong Special Administrative Region, China
| | - L Wang
- Collaborative Innovation Center of Radiological Medicine of Jiangsu Higher Education Institutions; School of Radiation Medicine and Protection, Medical College of Soochow University; School for Radiological and Interdisciplinary Sciences (RAD-X), Soochow University, Suzhou, Jiangsu, 215123, China.
| |
Collapse
|
48
|
Lin Z, Kuang Y, Hu N. Intrinsic bending stiffness of narrow graphene nanoribbons from quantum mechanics lattice dynamics calculations. Molecular Simulation 2021. [DOI: 10.1080/08927022.2020.1869734] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Affiliation(s)
- Z. Lin
- School of Mechanics and Construction Engineering, MOE Key Laboratory of Disaster Forecast and Control in Engineering, Jinan University Guangzhou, People’s Republic of China
| | - Y. Kuang
- School of Mechanics and Construction Engineering, MOE Key Laboratory of Disaster Forecast and Control in Engineering, Jinan University Guangzhou, People’s Republic of China
| | - N. Hu
- School of Mechanics and Construction Engineering, MOE Key Laboratory of Disaster Forecast and Control in Engineering, Jinan University Guangzhou, People’s Republic of China
| |
Collapse
|
49
|
Borland RL, Hu N, Tonge B, Einfeld S, Gray KM. Participation in sport and physical activity in adults with intellectual disabilities. J Intellect Disabil Res 2020; 64:908-922. [PMID: 33006215 DOI: 10.1111/jir.12782] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/23/2020] [Revised: 08/10/2020] [Accepted: 09/02/2020] [Indexed: 06/11/2023]
Abstract
BACKGROUND People with intellectual disability face a number of barriers to participation in physical activity. This paper aimed to determine rates of sport and physical activity participation in an Australian sample of adults with intellectual disability, compared with rates of participation in the general Australian population. A secondary aim was to investigate factors that may contribute to participation of adults with intellectual disability. METHOD Participants were part of the Australian Child to Adult Development (ACAD) study, consisting of a community sample with intellectual disability (n = 305), groups of adults with autism (n = 94), Down syndrome (n = 64), fragile X syndrome (n = 52), Williams syndrome (n = 45), and Prader-Willi syndrome (n = 30). Participation in sport/physical activity was reported over the past 3 months. Rates of participation were reported for adults with intellectual disability and compared with rates in a general Australian population sample. The relationship between participation in physical activity and age, degree of intellectual disability, physical mobility, living situation, socio-economic disadvantage, and behaviour and emotional problems were also conducted. RESULTS Participants in the ACAD community sample with intellectual disability participated in sport/physical activity at lower rates than the general Australian population (42% compared with 71%). Having no physical mobility impairment was significantly associated with higher rates of participation. Those with Down syndrome participated in sport/physical activity at higher rates than the community sample with intellectual disability, while no difference in sport/physical activity participation was observed in the groups with autism or other syndromes. CONCLUSION Australian adults with intellectual disability participate in sport and physical activity at lower rates than the general population. Having a physical mobility impairment was associated with lower rates of participation. However, people living in supported accommodation were more likely to participate than those in other living situations. Having Down syndrome was associated with a higher participation rate than the community sample.
Collapse
Affiliation(s)
- R L Borland
- Centre for Developmental Psychiatry and Psychology, Department of Psychiatry, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia
| | - N Hu
- Population Child Health Research Group, School of Women's and Children's Health, University of New South Wales, Australia
| | - B Tonge
- Centre for Developmental Psychiatry and Psychology, Department of Psychiatry, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia
- Centre for Educational Development, Appraisal and Research, University of Warwick, Coventry, UK
| | - S Einfeld
- Centre for Disability Research and Policy, Faculty of Health Sciences, University of Sydney, Sydney, New South Wales, Australia
| | - K M Gray
- Centre for Developmental Psychiatry and Psychology, Department of Psychiatry, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia
- Centre for Educational Development, Appraisal and Research, University of Warwick, Coventry, UK
| |
Collapse
|
50
|
Fukuo Y, Hattori Y, Kawabata S, Kashiwagi H, Kanemitsu T, Takeuchi K, Futamura G, Hiramatsu R, Watanabe T, Hu N, Takata T, Tanaka H, Suzuki M, Miyatake SI, Kirihata M, Wanibuchi M. The Therapeutic Effects of Dodecaborate Containing Boronophenylalanine for Boron Neutron Capture Therapy in a Rat Brain Tumor Model. Biology (Basel) 2020; 9:biology9120437. [PMID: 33271972 PMCID: PMC7759915 DOI: 10.3390/biology9120437] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/18/2020] [Revised: 11/26/2020] [Accepted: 11/29/2020] [Indexed: 11/22/2022]
Abstract
Simple Summary We have developed a new boron compound for application in boron neutron capture therapy (BNCT) named boronophenylalanine–amide alkyl dodecaborate (BADB). It is characterized by a larger amount of 10B per molecule, linking boronphenylalanine (BPA) and dodecaborate, and we conducted various experiments on its efficacy. Its high accumulation at the cellular level made it a promising novel drug, but it did not sufficiently accumulate in brain tumor tissue when intravenously administered. However, in neutron irradiation experiments, the drug showed remarkably high compound biological effectiveness and significantly prolonged the survival time in rat brain tumor models. We confirmed the antitumor efficacy of BADB in BNCT and its additional efficacy when administered in combination with BPA. Though this drug showed poor results when administered as a single agent, it was superior to BPA alone when administered in combination with BPA, making it a drug that we have been waiting for in our clinical practice. Abstract Background: The development of effective boron compounds is a major area of research in the study of boron neutron capture therapy (BNCT). We created a novel boron compound, boronophenylalanine–amide alkyl dodecaborate (BADB), for application in BNCT and focused on elucidating how it affected a rat brain tumor model. Methods: The boron concentration of F98 rat glioma cells following exposure to boronophenylalanine (BPA) (which is currently being utilized clinically) and BADB was evaluated, and the biodistributions in F98 glioma-bearing rats were assessed. In neutron irradiation studies, the in vitro cytotoxicity of each boron compound and the in vivo corresponding therapeutic effect were evaluated in terms of survival time. Results: The survival fractions of the groups irradiated with BPA and BADB were not significantly different. BADB administered for 6 h after the termination of convection-enhanced delivery ensured the highest boron concentration in the tumor (45.8 μg B/g). The median survival time in the BADB in combination with BPA group showed a more significant prolongation of survival than that of the BPA group. Conclusion: BADB is a novel boron compound for BNCT that triggers a prolonged survival effect in patients receiving BNCT.
Collapse
Affiliation(s)
- Yusuke Fukuo
- Department of Neurosurgery, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki-shi, Osaka 569-8686, Japan; (Y.F.); (H.K.); (T.K.); (K.T.); (G.F.); (R.H.); (M.W.)
| | - Yoshihide Hattori
- Research Center of Boron Neutron Capture Therapy, Research Organization for the 21st Century, Osaka Prefecture University, 1-1 Gakuen-cho, Nakaku, Sakai-shi, Osaka 599-8531, Japan; (Y.H.); (M.K.)
| | - Shinji Kawabata
- Department of Neurosurgery, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki-shi, Osaka 569-8686, Japan; (Y.F.); (H.K.); (T.K.); (K.T.); (G.F.); (R.H.); (M.W.)
- Correspondence: ; Tel.: +81-72-683-1221
| | - Hideki Kashiwagi
- Department of Neurosurgery, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki-shi, Osaka 569-8686, Japan; (Y.F.); (H.K.); (T.K.); (K.T.); (G.F.); (R.H.); (M.W.)
| | - Takuya Kanemitsu
- Department of Neurosurgery, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki-shi, Osaka 569-8686, Japan; (Y.F.); (H.K.); (T.K.); (K.T.); (G.F.); (R.H.); (M.W.)
| | - Koji Takeuchi
- Department of Neurosurgery, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki-shi, Osaka 569-8686, Japan; (Y.F.); (H.K.); (T.K.); (K.T.); (G.F.); (R.H.); (M.W.)
| | - Gen Futamura
- Department of Neurosurgery, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki-shi, Osaka 569-8686, Japan; (Y.F.); (H.K.); (T.K.); (K.T.); (G.F.); (R.H.); (M.W.)
| | - Ryo Hiramatsu
- Department of Neurosurgery, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki-shi, Osaka 569-8686, Japan; (Y.F.); (H.K.); (T.K.); (K.T.); (G.F.); (R.H.); (M.W.)
| | - Tsubasa Watanabe
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2 Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan; (T.W.); (T.T.); (H.T.); (M.S.)
| | - Naonori Hu
- Kansai BNCT Medical Center, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki-shi, Osaka 569-8686, Japan; (N.H.); (S.-I.M.)
| | - Takushi Takata
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2 Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan; (T.W.); (T.T.); (H.T.); (M.S.)
| | - Hiroki Tanaka
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2 Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan; (T.W.); (T.T.); (H.T.); (M.S.)
| | - Minoru Suzuki
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2 Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan; (T.W.); (T.T.); (H.T.); (M.S.)
| | - Shin-Ichi Miyatake
- Kansai BNCT Medical Center, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki-shi, Osaka 569-8686, Japan; (N.H.); (S.-I.M.)
| | - Mitsunori Kirihata
- Research Center of Boron Neutron Capture Therapy, Research Organization for the 21st Century, Osaka Prefecture University, 1-1 Gakuen-cho, Nakaku, Sakai-shi, Osaka 599-8531, Japan; (Y.H.); (M.K.)
| | - Masahiko Wanibuchi
- Department of Neurosurgery, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki-shi, Osaka 569-8686, Japan; (Y.F.); (H.K.); (T.K.); (K.T.); (G.F.); (R.H.); (M.W.)
| |
Collapse
|